Lipid nanoparticles comprising sterol-modified phospholipids
By using phospholipids containing sterol moieties, ionizable lipids and polymer-bound lipids in the lipid nanoparticles, the problem of insufficient nucleic acid delivery stability and permeability in the prior art is solved, and the intracellularity of mRNA is improved Expression level and treatment efficiency.
Patent Information
- Application Number
- CN202380035540.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-12-21
- Filing Date
- 2023-12-20
- Publication Date
- 2024-12-06
AI Technical Summary
Existing lipid nanoparticles have problems with stability and cell permeability when delivering nucleic acids to cells, affecting the effectiveness and efficiency of mRNA vaccines.
Lipid nanoparticles constructed with phospholipids containing sterol moieties, combined with ionizable lipids and polymer-bound lipids, improve bilayer stability and intracellular delivery efficiency by adjusting molar ratios and structural design.
显著提高了mRNA的细胞内表达水平,增强了基于mRNA的治疗和疗法的有效性和效率,降低了副作用的出现。
Smart Images

Figure BDA0005095482150000011 
Figure BDA0005095482150000021 
Figure BDA0005095482150000022
Abstract
Description
Technical Field
[0001] The present invention relates to lipid nanoparticles comprising phospholipids containing a sterol moiety. Background Art
[0002] Lipid nanoparticles (or LNPs) are known vehicles for delivering bioactive agents to cells. Due to the problems of in vivo stability and cell permeability of nucleic acids alone, LNPs have recently become particularly important in delivering nucleic acids to cells. An important application of LNPs loaded with nucleic acids is mRNA vaccines. Summary of the invention
[0003] The application provides the phospholipid containing sterol moiety that can be used for building lipid nanoparticles. In one aspect, lipid nanoparticles can be used for nucleic acid (e.g., mRNA) to be delivered to one or more cells. In one aspect, the application provides a method for expressing protein in cells, the method being carried out by delivering nucleic acid to cells via lipid nanoparticles comprising the phospholipid containing sterol moiety.
[0004] Also provided herein are lipid nanoparticles (LNPs) comprising:
[0005] Phospholipids containing a sterol moiety;
[0006] Ionizable lipids; and
[0007] Polymer-bound lipids.
[0008] In some embodiments, the phospholipid has a structure selected from the group consisting of:
[0009]
[0010] as well as
[0011]
[0012] In some embodiments, the phospholipid has the following structure:
[0013]
[0014] In some embodiments, the phospholipid has the following structure:
[0015]
[0016] In some embodiments, LNP has the mol ratio of ionizable lipid to phospholipid of 20:1 to 2:1.In some embodiments, the mol ratio of ionizable lipid to phospholipid is 15:1 to 5:1.In some embodiments, ionizable lipid accounts for 40 to 80mol% of the total lipid amount in LNP.In some embodiments, ionizable lipid accounts for 50 to 70mol% of the total lipid amount in LNP.In some embodiments, ionizable lipid is cationic lipid.In some embodiments, ionizable lipid is according to the formula selected from 01-I, 01-II, 02-I, 02-II, 03-I, 03-II-A, 03-II-B, 03-II-C, 03-II-D, 04-I, 04-III, 04-IV, 05-I, 06-I and any one of its subformula compounds, or wherein ionizable lipid is the cationic lipid of the compound listed in any one of table 1 to table 5.
[0017] In some embodiments, the polymer-bound lipid accounts for 0.5 to 5 mol% of the total lipid amount in the LNP. In some embodiments, the polymer-bound lipid accounts for 1 to 2 mol% of the total lipid amount in the LNP. In some embodiments, the polymer-bound lipid accounts for 1.5 mol% of the total lipid amount in the LNP. In some embodiments, the LNP has a molar ratio of polymer-bound lipid to phospholipid of 1:2 to 1:20. In some embodiments, the LNP has a molar ratio of polymer-bound lipid to phospholipid of 1:3 to 1:18. In some embodiments, the LNP has a molar ratio of polymer-bound lipid to phospholipid of 1:5 to 1:10. In some embodiments, the polymer-bound lipid is a pegylated lipid. In some embodiments, the polymer-bound lipid is a pegylated lipid having the following structure:
[0018]
[0019] or a pharmaceutically acceptable salt thereof, wherein
[0020] R 12 and R 13 Each is independently a straight or branched alkyl or alkenyl chain containing from 10 to 30 carbon atoms, wherein the alkyl chain is optionally interrupted by one or more ester bonds; and
[0021] w is an integer in the range of 30 to 60.
[0022] In some embodiments, the polymer-bound lipid is a PEGylated lipid having the following structure:
[0023]
[0024] or a pharmaceutically acceptable salt thereof, wherein
[0025] w is an integer in the range of 30 to 60.
[0026] In some embodiments of any of the above structures, w is an integer in the range of 45 to 55.
[0027] In some embodiments, w is about 49.
[0028] In some embodiments, the polymer-bound lipid is DMG-PEG or DMPE-PEG.
[0029] In some embodiments, the LNP further comprises a lipid stabilizer.
[0030] In some embodiments, the LNP has a lipid stabilizer to phospholipid molar ratio of 10: 1 to 1: 4. In some embodiments, the lipid stabilizer to phospholipid molar ratio is 5: 1 to 1: 3. In some embodiments, the LNP has a lipid stabilizer to phospholipid molar ratio of 10: 1 to 1: 2. In some embodiments, the lipid stabilizer to phospholipid molar ratio is 5: 1 to 1: 1. In some embodiments, the lipid stabilizer to phospholipid molar ratio is 4: 1 to 3: 1.
[0031] In some embodiments, the lipid stabilizer accounts for 5 to 50 mol% of the total lipid in the LNP. In some embodiments, the lipid stabilizer accounts for 8 to 40 mol% of the total lipid in the LNP. In some embodiments, the lipid stabilizer accounts for 10 to 30 mol% of the total lipid in the LNP.
[0032] In some embodiments, phospholipids account for 1 to 30 mol% of the total lipids in the LNP. In some embodiments, phospholipids account for 2 to 25 mol% of the total lipids in the LNP. In some embodiments, phospholipids account for 3 to 20 mol% of the total lipids in the LNP. In some embodiments, phospholipids account for 5 to 15 mol% of the total lipids in the LNP. In some embodiments, phospholipids account for about 10 mol% of the total lipids in the LNP.
[0033] In some embodiments, the LNP has a size of 20nm to 300nm as measured using dynamic light scattering. In some embodiments, the LNP has a size of 50nm to 150nm as measured using dynamic light scattering. In some embodiments, the size is 60nm to 140nm. In some embodiments, the size is 80nm to 100nm. In some embodiments, the size is 85nm to 95nm.
[0034] In some embodiments, the LNP encapsulates mRNA.
[0035] Also provided herein are LNPs comprising a phospholipid, wherein the phospholipid has the following structure:
[0036]
[0037] as well as
[0038]
[0039] In some embodiments, the phospholipid has the following structure:
[0040]
[0041] In some embodiments, the phospholipid has the following structure:
[0042]
[0043] In some embodiments, the LNP further comprises an ionizable lipid.
[0044] In some embodiments, LNP has the mol ratio of ionizable lipid to phospholipid of 20: 1 to 2: 1. In some embodiments, the mol ratio of ionizable lipid to phospholipid is 15: 1 to 5: 1. In some embodiments, ionizable lipid accounts for 40 to 80mol% of the total lipid amount in LNP. In some embodiments, ionizable lipid accounts for 50 to 70mol% of the total lipid amount in LNP. In some embodiments, ionizable lipid is according to the formula selected from 01-I, 01-II, 02-I, 02-II, 03-I, 03-II-A, 03-II-B, 03-II-C, 03-II-D, 04-I, 04-III, 04-IV, 05-I, 06-I and any one of its subformula compounds, or wherein ionizable lipid is a cationic lipid selected from the compound listed in any one of Table 1 to Table 5. In some embodiments, ionizable lipid is a cationic lipid.
[0045] In some embodiments, LNP also comprises polymer-bound lipid.In some embodiments, polymer-bound lipid accounts for 1 to 2mol% of the total lipid amount in LNP.In some embodiments, polymer-bound lipid accounts for 1.5% of the total lipid amount in LNP.In some embodiments, LNP has a polymer-bound lipid and a phospholipid mol ratio of 1:5 to 1:10.In some embodiments, polymer-bound lipid is a pegylated lipid.
[0046] In some embodiments, the polymer-bound lipid is a PEGylated lipid having the following structure:
[0047]
[0048] or a pharmaceutically acceptable salt thereof, wherein
[0049] R 12 and R 13 Each is independently a straight or branched alkyl or alkenyl chain containing from 10 to 30 carbon atoms, wherein the alkyl chain is optionally interrupted by one or more ester bonds; and
[0050] w is an integer in the range of 30 to 60.
[0051] In some embodiments, the polymer-bound lipid is a PEGylated lipid having the following structure:
[0052]
[0053] or a pharmaceutically acceptable salt thereof, wherein
[0054] w is an integer in the range of 30 to 60.
[0055] In some embodiments of any of the above structures, w is an integer in the range of 45 to 55. In some embodiments, w is about 49.
[0056] In some embodiments, the polymer-bound lipid is DMG-PEG or DMPE-PEG.
[0057] In some embodiments, LNP also includes lipid stabilizers. In some embodiments, LNP has a lipid stabilizer to phospholipid molar ratio of 10: 1 to 1: 4. In some embodiments, the lipid stabilizer to phospholipid molar ratio is 5: 1 to 1: 3. In some embodiments, the lipid stabilizer to phospholipid molar ratio is 4: 1 to 3: 1. In some embodiments, lipid stabilizers account for 5 to 50 mol% of the total lipid amount in LNP. In some embodiments, lipid stabilizers account for 8 to 40 mol% of the total lipid amount in LNP. In some embodiments, lipid stabilizers account for 10 to 30 mol% of the total lipid amount in LNP.
[0058] In some embodiments, phospholipids account for 1 to 30mol% of the total lipid amount in LNP. In some embodiments, phospholipids account for 2 to 25mol% of the total lipid amount in LNP. In some embodiments, phospholipids account for 3 to 20mol% of the total lipid amount in LNP. In some embodiments, phospholipids account for 5 to 15mol% of the total lipid amount in LNP. In some embodiments, phospholipids account for about 10mol% of the total lipid amount in LNP. In some embodiments, as measured using dynamic light scattering, LNP has a size of 20nm to 300nm. In some embodiments, as measured using dynamic light scattering, LNP has a size of 50nm to 150nm. In some embodiments, a size of 60nm to 140nm. In some embodiments, a size of 80nm to 100nm. In some embodiments, a size of 85nm to 95nm.
[0059] In some embodiments, the LNP encapsulates mRNA.
[0060] Also provided herein are compositions of lipid nanoparticles (LNPs) described herein. In some embodiments, at least 80% of the LNPs encapsulate mRNA. In some embodiments, at least 85% of the LNPs encapsulate mRNA.
[0061] Also provided herein are methods for expressing a protein in a cell, the method comprising introducing a LNP as described herein into the cell. In some embodiments, the cell is a mammalian cell.
[0062] Also provided herein is a method for delivering a protein to a subject, the method comprising administering to an individual an LNP as described herein or a composition thereof, wherein the mRNA encodes the protein. In some embodiments, the LNP or a composition thereof is systemically administered. In some embodiments, the subject is a mammal. In some embodiments, the subject is a human. BRIEF DESCRIPTION OF THE DRAWINGS
[0063] The drawings illustrate certain embodiments of the features and advantages of the present disclosure. These embodiments are not intended to limit the scope of the appended claims in any way.
[0064] Figure 1 The hEPO expression levels in LNP formulations containing PChemsPC or OChemsPC in Example 15 having a molar ratio of Compound 01-1 / OChemsPC or PChemsPC / Chol / DMG-PEG of 60:10:28.5:1.5 are shown.
[0065] Figure 2The hEPO expression levels in LNP formulations containing various mole percentages of DSPC or PChemsPC in Example 16 are shown.
[0066] Figure 3 The hEPO expression levels in LNP formulations of PChemsPC containing various molar ratios of PChemsPC / cholesterol in Example 17 are shown.
[0067] Figure 4 Luminescence levels measured from liver tissue harvested in Example 19 are shown.
[0068] Figure 5 The percentage of luminescence intensity in different tissues in Example 19 is shown.
[0069] Figure 6 The fold change of hEPO expression with or without LNPs containing steroid phospholipids in Example 20 is shown.
[0070] Figure 7 The serum cytokine levels enhanced by Compound 01-1 LNPs in Example 21 are shown.
[0071] Figure 8 Shown are serum cytokine levels enhanced by lipid 5 LNPs in Example 21.
[0072] Fig. 9 The serum cytokine levels enhanced by SM-102 LNPs in Example 21 are shown.
[0073] Fig.10 The serum cytokine levels enhanced by ALC-0315 LNPs in Example 21 are shown.
[0074] Fig.11 The serum cytokine levels enhanced by Compound 03-135 LNPs in Example 21 are shown.
[0075] Fig.12 Shown are serum cytokine levels enhanced by Compound 01-1 saRNA-LNPs in Example 22.
[0076] Fig.13 Shown are serum cytokine levels enhanced by Compound 03-135 saRNA-LNPs in Example 22.
[0077] Fig.14 CD3-CD19 antibody levels with and without steroid phospholipid-containing LNPs in Example 23 are shown. DETAILED DESCRIPTION
[0078] Provided herein are LNPs comprising phospholipids containing sterol moieties. LNPs can be loaded with mRNA, such as in mRNA vaccine technology. Sterol-modified phospholipids stabilize the bilayer, but are not freely exchanged between membranes like cholesterol. Compared with LNPs loaded with mRNA having more conventional phospholipids, the LNPs loaded with mRNA show the ability to increase protein expression in target cells. Increasing protein expression helps to improve the effectiveness and efficiency of mRNA-based treatments and therapies.
[0079] I. Definitions
[0080] As used herein, "pharmaceutically acceptable" or "pharmacologically compatible" means that the material is not biologically or otherwise undesirable, e.g., the material can be incorporated into a pharmaceutical composition administered to a patient without causing any significant undesirable biological effect or interacting in a deleterious manner with any of the other components contained in the composition. Pharmaceutically acceptable carriers or excipients preferably meet the required standards of toxicology and manufacturing testing and / or are included in the Inactive Ingredient Guide prepared by the US Food and Drug Administration.
[0081] As used herein, "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable substrate, composition or vehicle used in the process of drug delivery, which may have one or more components, including but not limited to one or more excipients, one or more binders, one or more diluents, one or more solvents, one or more fillers and / or one or more stabilizers.
[0082] As used herein, the term "lipid" refers to a group of compounds including, but not limited to, fats, sterols, waxes, fat-soluble vitamins, monoglycerides, diglycerides, sphingolipids, and phospholipids. In the context of the present disclosure, phospholipids, ionizable lipids, polymer-bound lipids, and lipid stabilizers are considered to be lipids.
[0083] As used herein, the term "ionizable lipid" refers to a lipid having a non-zero net charge at physiological pH. The term includes cationic lipids, including lipids having a partial positive charge at physiological pH. The term also includes mixtures of ionizable lipids, which may contain two or more ionizable lipids. In each case where an embodiment is considered with the term "ionizable lipid", it is also considered with "cationic lipid", as if all embodiments were specifically and individually listed with both ionizable lipids and cationic lipids.
[0084] As used herein, the term "polymer-bound lipid" refers to a lipid comprising a polymer portion. The term includes PEGylated lipids, including PEGylated phosphatidylethanolamine, PEGylated phosphatidic acid, PEGylated ceramide, PEGylated dialkylamine, PEGylated diacylglycerol and PEGylated dialkylglycerol. The term also includes a mixture of polymer-bound lipids, which may contain two or more polymer-bound lipids. In each case where an embodiment is considered with the term "polymer-bound lipid", it is also considered with "PEGylated lipid", as if all embodiments are specifically and individually listed with both polymer-bound lipids and PEGylated lipids.
[0085] As used herein, the term "lipid stabilizer" refers to a component in a lipid nanoparticle that is believed to help stabilize the LNP structure. Without being bound by theory, it is believed that the lipid stabilizer component of the LNP helps support the liquid ordered phase of the lipid membrane in the LNP. See, for example, Albertsen, HC, et al., "The role of lipid components in lipid nanoparticles for vaccines and gene therapy." Adv Drug Deliv Rev. 2022 Sep; 188: 114416, section 3.3.1. Compounds that can act as lipid stabilizers include steroids, corticosteroids, vitamins, and other compounds containing a steroid core.
[0086] As used herein, the term "alkyl" refers to a chain of carbon atoms in which all bonds between carbon atoms in the alkyl group are single bonds. The term includes straight and branched chains (eg, the term includes n-propyl and isopropyl).
[0087] As used herein, the term “C x -C y "C1-C3 alkyl" refers to an alkyl group having at least x carbon atoms and no more than y carbon atoms in the alkyl chain. For example, the term "C1-C3 alkyl" includes, but is not limited to, methyl, ethyl, n-propyl, and isopropyl.
[0088] As used herein, the term "alkylene" refers to an alkyl chain that is attached to other chemical groups at at least two positions. x -C y "Alkylene" refers to an alkylene group having at least x carbon atoms and no more than y carbon atoms in the alkylene chain. For example, the term "C1-C3 alkylene" includes, but is not limited to, methylene, ethylene, n-propylene, and isopropylene.
[0089] As used herein, the term "alkenyl" refers to a chain of carbon atoms having at least one double bond between two carbon atoms in the chain. The term includes straight and branched chains (eg, the term includes 1-propenyl and isopropenyl).
[0090] As used herein, the term “C x -C y "Alkenyl" refers to an alkenyl group having at least x carbon atoms and no more than y carbon atoms in the alkenyl chain. For example, the term "C2-C4 alkenyl" includes, but is not limited to, ethenyl and 1-propenyl.
[0091] As used herein, the term "alkenylene" refers to an alkenyl chain that is attached to other chemical groups at at least two positions. x -C y "Alkenylene" refers to an alkenylene group having at least x carbon atoms and no more than y carbon atoms.
[0092] As used herein, the term "alkynyl" refers to a chain of carbon atoms having at least one triple bond between two carbon atoms in the chain. The term includes straight and branched chains (e.g., the term includes 1-propynyl and isopropynyl).
[0093] As used herein, the term “C x -C y "Alkynyl" refers to an alkynyl group having at least x carbon atoms and no more than y carbon atoms in the alkynyl chain.
[0094] As used herein, the term "cycloalkyl" refers to a cyclic group of carbon atoms in which all bonds between the carbon atoms are single bonds. x -C y "Cycloalkyl" refers to a cycloalkyl group having at least x carbon atoms and not more than y carbon atoms. For example, the term "C6-C 10 "Cycloalkyl" includes, but is not limited to, cyclohexyl and cyclooctyl. The term "cycloalkylene" has the same meaning as cycloalkyl, except that the cycloalkylene is attached to at least two other chemical groups.
[0095] As used herein, the term "cycloalkenyl" refers to a cyclic group of carbon atoms, wherein at least one bond between two carbon atoms in the cycloalkenyl group is a double bond. x -C y "Cycloalkenyl" refers to a cycloalkenyl group having at least x carbon atoms and not more than y carbon atoms.
[0096] The term "C x -C y "Aryl" refers to an aromatic group having at least x carbon atoms and not more than y carbon atoms. For example, the term "C6-C 10"Aryl" includes, but is not limited to, phenyl and naphthyl. The term "arylene" has the same meaning as aryl, except that the arylene group is linked to at least two other chemical groups.
[0097] As used herein, the term "heterocycloalkyl" refers to a cyclic group of atoms in which all bonds between atoms in the ring are single bonds. x -C y "Heterocycloalkyl" refers to a heterocycloalkyl group having at least x atoms and not more than y atoms. For example, the term "C5-C6 heterocycloalkyl" includes, but is not limited to, pyrrolidinyl and 1,4-dioxanyl. The term "heterocycloalkylene" has the same meaning as heterocycloalkyl, except that the heterocycloalkylene group is attached to at least two other chemical groups.
[0098] The term "x to y membered heteroaryl" refers to a cyclic atom group having at least x atoms and no more than y atoms. For example, 5-membered or 6-membered heteroaryl groups include, but are not limited to, pyridyl and furyl.
[0099] As used herein, the term "carbocycle" refers to a cycloalkyl or aryl group. Likewise, the term "heterocycle" refers to a heterocycloalkyl or heteroaryl group.
[0100] Possible atoms constituting the rings in heterocycloalkyl and heteroaryl groups and derivatives thereof include, but are not limited to, carbon, nitrogen, oxygen and sulfur.
[0101] As used herein, the term "optionally substituted" means that the indicated group can be substituted or unsubstituted. The term substituted refers to modifying another chemical moiety of the indicated group by replacing one H atom. For example, ethanol is an example of ethane substituted with OH. In some embodiments, the optionally substituted group is optionally replaced by chloro, fluoro, bromo, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C7 cycloalkyl, C6-C 10 aryl or 5- or 6-membered heteroaryl.
[0102] The terms "individual," "subject," and "patient" are used interchangeably herein to describe mammals, including humans. In some embodiments, the individual is in need of treatment, for example, the individual may have been diagnosed with or is suspected of having cancer.
[0103] It should be understood that the embodiments of the present invention described herein include "consisting of" and / or "consisting essentially of" the embodiments.
[0104] Reference herein to "about" a value or parameter includes (and describes) deviations about the value or parameter itself. For example, a description referring to "about X" includes describing "X". In some embodiments, the term "about" a value or parameter refers to a range within 20% in either direction of the value or parameter.
[0105] As used herein, reference to "not being" a value or parameter generally means and describes "except for" a value or parameter.
[0106] As used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
[0107] As used herein and in the appended claims, the mole percentages of lipids and lipid stabilizers in lipid nanoparticles are calculated based on the total moles of components in the lipid nanoparticles.
[0108] II. Lipid Nanoparticles (LNP)
[0109] Lipid nanoparticles (LNP) herein include phospholipids containing sterol moieties and optionally one or more of ionizable lipids, polymer-bound lipids and lipid stabilizers. In some embodiments, LNP includes phospholipids containing sterol moieties, ionizable lipids and polymer-bound lipids. In some embodiments, LNP includes phospholipids containing sterol moieties, polymer-bound lipids and lipid stabilizers. In some embodiments, LNP includes phospholipids containing sterol moieties, ionizable lipids and lipid stabilizers. In some embodiments, LNP includes phospholipids containing sterol moieties, ionizable lipids, polymer-bound lipids and lipid stabilizers. In some embodiments, LNP includes phospholipids containing sterol moieties, ionizable lipids, polymer-bound lipids and lipid stabilizers.
[0110] In some embodiments, phospholipids account for 1 to 30 mol% of the total lipids in the LNP. In some embodiments, phospholipids account for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 mol% of the total lipids in the LNP. In some embodiments, phospholipids account for 2 to 25 mol% of the total lipids in the LNP. In some embodiments, phospholipids account for 3 to 20 mol% of the total lipids in the LNP. In some embodiments, phospholipids account for 5 to 10, 15, 20, 25, or 30 mol% of the total lipids in the LNP. In some embodiments, phospholipids account for 10 to 15, 20, 25, or 30 mol% of the total lipids in the LNP. In some embodiments, phospholipids account for 15 to 20, 25, or 30 mol% of the total lipids in the LNP. In some embodiments, the phospholipids comprise 20 to 25 or 30 mol % of the total lipids in the LNP. In some embodiments, the phospholipids comprise 25 to 30 mol % of the total lipids in the LNP.
[0111] In some embodiments, the ionizable lipids account for 40 to 80 mol% of the total lipids in the LNP. In some embodiments, the ionizable lipids account for 40 to 50, 60, 70, or 80 mol% of the total lipids in the LNP. In some embodiments, the ionizable lipids account for 45 to 50, 60, 70, 75, or 80 mol% of the total lipids in the LNP. In some embodiments, the ionizable lipids account for 50 to 60, 70, or 80 mol% of the total lipids in the LNP. In some embodiments, the ionizable lipids account for 60 to 65, 70, or 80 mol% of the total lipids in the LNP. In some embodiments, the ionizable lipids account for 70 to 80 mol% of the total lipids in the LNP. In some embodiments, the ionizable lipids account for about 40, 50, 60, 70, or 80 mol% of the total lipids in the LNP. In some embodiments, the ionizable lipids account for about 50, 60, or 70 mol% of the total lipids in the LNP.
[0112] In some embodiments, the LNP has a molar ratio of ionizable lipids to phospholipids of 20: 1 to 2: 1. In some embodiments, the molar ratio is 20: 1 to 15: 1, 10: 1, 5: 1 or 2: 1. In some embodiments, the molar ratio is 18: 1 to 2.5: 1. In some embodiments, the molar ratio is 16: 1 to 4: 1. In some embodiments, the molar ratio is 15: 1 to 10: 1, 5: 1 or 2: 1. In some embodiments, the molar ratio is 10: 1 to 5: 1 or 2: 1. In some embodiments, the ratio is 5: 1 to 2: 1. In some embodiments, the ratio is 15: 1 to 5: 1.
[0113] In some embodiments, the polymer-bound lipid has a molar ratio of 0.5 to 5 mol% of the total lipid in the LNP. In some embodiments, the polymer-bound lipid has a molar ratio of 1 to 2 mol% of the total lipid in the LNP. In some embodiments, the polymer-bound lipid has a molar ratio of 1.5 mol% of the total lipid in the LNP.
[0114] In some embodiments, the molar ratio of polymer-bound lipid to phospholipid is 1:2 to 1:20. In some embodiments, the molar ratio of polymer-bound lipid to phospholipid is 1:3 to 1:18. In some embodiments, the molar ratio of polymer-bound lipid to phospholipid is 1:5 to 1:10.
[0115] In some embodiments, the lipid stabilizer accounts for 5 to 50 mol% of the total lipids in the LNP. In some embodiments, the lipid stabilizer accounts for 5 to 10, 20, 30, 40 or 50 mol% of the total lipids in the LNP. In some embodiments, the lipid stabilizer accounts for 8 to 20, 30, 40 or 50 mol% of the total lipids in the LNP. In some embodiments, the lipid stabilizer accounts for 10 to 20, 30, 40 or 50 mol% of the total lipids in the LNP. In some embodiments, the lipid stabilizer accounts for 20 to 30, 40 or 50 mol% of the total lipids in the LNP. In some embodiments, the lipid stabilizer accounts for 30 to 40 or 50 mol% of the total lipids in the LNP. In some embodiments, the lipid stabilizer accounts for 40 to 50 mol% of the total lipids in the LNP. In some embodiments, the lipid stabilizer accounts for about 5, 10, 20, 30, 40 or 50 mol% of the total lipids in the LNP.
[0116] It should be understood that in any embodiment describing the lipid composition of the LNP described herein, any of the mole percentages or mole ratios described above for the sterol-containing phospholipids, ionizable lipids, polymer-bound lipids, and lipid stabilizers can be combined with each other, such that each combination is contemplated as if each combination was specifically and individually disclosed.
[0117] In some embodiments, phospholipids account for 1 to 30 mol% of the total lipids in LNP, ionizable lipids account for 40 to 80 mol%, polymer-bound lipids account for 1 to 2 mol%, and lipid stabilizers account for 5 to 50 mol%. In some embodiments, phospholipids account for 5 to 25 mol% of the total lipids in LNP, ionizable lipids account for 45 to 75 mol%, polymer-bound lipids account for 1 to 2 mol%, and lipid stabilizers account for 20 to 40%. In some embodiments, phospholipids account for 5 to 15 mol% of the total lipids in LNP, ionizable lipids account for 40 to 60 mol%, polymer-bound lipids account for 1 to 2 mol%, and lipid stabilizers account for 20 to 40 mol%. In some embodiments, phospholipids account for about 10 mol% of the total lipids in LNP, ionizable lipids account for about 50 mol%, polymer-bound lipids account for about 38.5 mol%, and lipid stabilizers account for about 1.5 mol%.
[0118] In some embodiments, LNP has a size of 20 to 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 200, 250 or 300nm. In some embodiments, the size is 40 to 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 200, 250 or 300nm. In some embodiments, the size is 50 to 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 200, 250 or 300nm. In some embodiments, the size is 60 to 70, 80, 90, 100, 110, 120, 130, 140, 150, 200, 250 or 300nm. In some embodiments, the size is 70 to 80, 90, 100, 110, 120, 130, 140, 150, 200, 250 or 300nm. In some embodiments, the size is 80 to 90, 100, 110, 120, 130, 140, 150, 200, 250 or 300nm. In some embodiments, the size is 90 to 100, 110, 120, 130, 140, 150, 200, 250 or 300nm. In some embodiments, the size is 100 to 110, 120, 130, 140, 150, 200, 250 or 300nm. In some embodiments, the size is 110 to 120, 130, 140, 150, 200, 250 or 300nm. In some embodiments, the size is 120 to 130, 140, 150, 200, 250 or 300nm. In some embodiments, the size is 130 to 140, 150, 200, 250 or 300nm. In some embodiments, the size is 140 to 150, 200, 250 or 300nm. In some embodiments, the size is 150 to 200, 250 or 300nm. In some embodiments, the size is 200 to 300nm. In some embodiments, the size is 60 to 150nm. In some embodiments, the size is 65 to 90nm. In some embodiments, the size is 70 to 80nm. In some embodiments, the size is about 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110 or 115nm. In some embodiments, the size is about 85 or about 90nm. In some embodiments, the size is about 85nm. In some embodiments, the size is about 90 nm.
[0119] A. Phospholipids containing sterol moieties
[0120] LNP herein comprises the phospholipid containing sterol moiety.The phospholipid containing sterol moiety is any phospholipid that sterol moiety is merged into lipid structure.In some embodiments, merge sterol moiety to replace one or more alkyl chains on phospholipid.In some embodiments, sterol moiety is merged into an alkyl chain of phospholipid.In some embodiments, sterol moiety is connected by the O atom of sterol (for example, sterol moiety is converted into-O-atom of the ester that is connected to the remainder of phospholipid).In some embodiments, sterol moiety is cholesterol.In some embodiments, sterol moiety is the cholesterol moiety that is connected by the O atom of sterol (for example, by the sterol O atom of cholesterol is converted into-O-atom of the ester that is connected to the remainder of phospholipid).
[0121] In some embodiments, the phospholipid has a structure selected from the group consisting of:
[0122]
[0123] as well as
[0124]
[0125] B. Ionizable lipids
[0126] In some embodiments, LNP comprises ionizable lipids. In some embodiments, the ionizable lipids are cationic lipids. In some embodiments, the cationic lipids are cationic lipids described in International Patent Publication No. WO 2021 / 204175, the entirety of which is incorporated herein by reference.
[0127] In some embodiments, the cationic lipid is a compound of formula (01-I):
[0128]
[0129] or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, wherein:
[0130] G 1 and G 2 Each independently is a bond, C2-C 12 Alkylene or C2-C 12 Alkenylene, wherein one or more -CH2- in the alkylene or alkenylene group is optionally replaced by -O-;
[0131] L 1 =–OC(=O)R 1 、-C(=O)OR 1 、-OC(=O)OR 1 、-C(=O)R 1 、-OR 1, -S(O)xR 1 , -S-SR 1 , -C(=O)SR 1 , -SC(=O)R 1 , -NR a C(=O)R 1 , -C(=O)NR b R c , -NR a C(=O)NR b R c , -OC(=O)NR b R c , -NR a C(=O)OR 1 , -SC(=S)R 1 , -C(=S)SR 1 , -C(=S)R 1 , -CH(OH)R 1 , -P(=O)(OR b )(OR c ), -(C6-C 10 arylene)-R 1 , -(6 to 10-membered heteroarylene)-R 1 or R 1 ;
[0132] L 2 is –OC(=O)R 2 , -C(=O)OR 2 , -OC(=O)OR 2 , -C(=O)R 2 , -OR 2 , -S(O) x R 2 , -S-SR 2 , -C(=O)SR 2 , -SC(=O)R 2 , -NR d C(=O)R 2 , -C(=O)NR e R f , -NR d C(=O)NR e R f , -OC(=O)NR e R f , -NR d C(=O)OR 2 , -SC(=S)R 2 , -C(=S)SR 2 , -C(=S)R 2、-CH(OH)R 2 、-P(=O)(OR e )(OR f )、-(C6-C 10 Arylene)-R 2 , -(6- to 10-membered heteroarylene)-R 2 or R 2 ;
[0133] R 1 and R 2 Each independently is C6-C 32 Alkyl or C6-C 32 alkenyl;
[0134] R a , R b , R d and R e Each independently is H, C1-C 24 Alkyl or C2-C 24 alkenyl;
[0135] R c and R f Each independently is C1-C 32 Alkyl or C2-C 32 alkenyl;
[0136] G 3 and C2-C 24 Alkylene, C2-C 24 Alkenylene, C3-C8 cycloalkylene or C3-C8 cycloalkenylene;
[0137] R 3 -N(R 4 )R 5 ;
[0138] R 4 is a C3-C8 cycloalkyl, a C3-C8 cycloalkenyl, a 4- to 8-membered heterocyclic group or a C6-C 10 Aryl; or R 4 , G 3 or G 3 A portion of forms a cyclic portion together with the nitrogen to which it is attached;
[0139] R 5 C1-C 12 Alkyl or C3-C8 cycloalkyl; or R 4 , R 5 Together with the nitrogen to which it is attached, it forms a cyclic portion;
[0140] x is 0, 1, or 2; and
[0141] wherein each alkyl, alkenyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, alkylene, alkenylene, cycloalkylene, cycloalkenylene, arylene, heteroarylene, and cyclic moiety is independently optionally substituted.
[0142] In some embodiments, the cationic lipid is a compound of formula (01-II):
[0143]
[0144] or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, wherein:
[0145] is a single bond or a double bond;
[0146] G 1 and G 2 Each independently is a bond, C2-C 12 Alkylene or C2-C 12 Alkenylene, wherein one or more -CH2- in the alkylene or alkenylene group is optionally replaced by -O-;
[0147] L 1 =–OC(=O)R 1 、-C(=O)OR 1 、-OC(=O)OR 1 、-C(=O)R 1 、-OR 1 、-S(O) x R 1 、-S-SR 1 、-C(=O)SR 1 、-SC(=O)R 1 、-NR a C(=O)R 1 、-C(=O)NR b R c 、-NR a C(=O)NR b R c 、-OC(=O)NR b R c 、-NR a C(=O)OR 1 、-SC(=S)R 1 、-C(=S)SR 1 、-C(=S)R 1 、-CH(OH)R 1 、-P(=O)(OR b )(OR c )、-(C6-C 10 Arylene)-R 1, -(6- to 10-membered heteroarylene)-R 1 or R 1 ;
[0148] L 2 =–OC(=O)R 2 、-C(=O)OR 2 、-OC(=O)OR 2 、-C(=O)R 2 、-OR 2 、-S(O) x R 2 、-S-SR 2 、-C(=O)SR 2 、-SC(=O)R 2 、-NR d C(=O)R 2 、-C(=O)NR e R f 、-NR d C(=O)NR e R f 、-OC(=O)NR e R f 、-NR d C(=O)OR 2 、-SC(=S)R 2 、-C(=S)SR 2 、-C(=S)R 2 、-CH(OH)R 2 、-P(=O)(OR e )(OR f )、-(C6-C 10 Arylene)-R 2 , -(6- to 10-membered heteroarylene)-R 2 or R 2 ;
[0149] R 1 and R 2 Each independently is C6-C 32 Alkyl or C6-C 32 alkenyl;
[0150] R a , R b , R d and R e Each independently is H, C1-C 24 Alkyl or C2-C 24 alkenyl;
[0151] R c and R f Each independently is C1-C32 Alkyl or C2-C 32 alkenyl;
[0152] G 4 is a key, C1-C 23 Alkylene, C2-C 23 Alkenylene, C3-C8 cycloalkylene or C3-C8 cycloalkenylene;
[0153] R 3 -N(R 4 )R 5 ;
[0154] R 4 C1-C 12 Alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, 4- to 8-membered heterocyclic group or C6-C 10 Aryl; or R 4 , G 3 or G 3 A portion of forms a cyclic portion together with the nitrogen to which it is attached;
[0155] R 5 C1-C 12 Alkyl or C3-C8 cycloalkyl; or R 4 and R 5 Together with the nitrogen to which it is attached, it forms a cyclic portion;
[0156] x is 0, 1, or 2; and
[0157] wherein each alkyl, alkenyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, alkylene, alkenylene, cycloalkylene, cycloalkenylene, arylene, heteroarylene, and cyclic moiety is independently optionally substituted.
[0158] In some embodiments, the cationic lipid is a compound of formula (01-IB), (01-I-B'), (01-IB"), (01-IC), (01-ID), or (01-IE):
[0159]
[0160]
[0161] or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof.
[0162] In some embodiments, G 1 and G 2 Each is independently C3-C7 alkylene. 1 and G 2 Each is independently C5 alkylene.3 is C2-C4 alkylene. 3 In some embodiments, G 3 It is a C4 alkylene group.
[0163] In some embodiments, R 3 Has one of the following structures:
[0164]
[0165] In some embodiments, R 1 , R 2 , R c and R f Each independently is a branched chain C6-C 32 Alkyl or branched chain C6-C 32 In some embodiments, R 1 , R 2 , R c and R f Each independently is a branched chain C6-C 24 Alkyl or branched chain C6-C 24 In some embodiments, R 1 , R 2 , R c and R f Each independently is -R 7 -CH(R 8 )(R 9 ), where R 7 is C0-C5 alkylene, and R 8 and R 9 Independently for C2-C 10 In some embodiments, R 1 , R 2 , R c and R f Each independently is -R 7 -CH(R 8 )(R 9 ), where R 7 is C0-C1 alkylene, and R 8 and R 9 are independently C4-C8 alkyl.
[0166] In some embodiments, the cationic lipid is a compound in Table 1 or a pharmaceutically acceptable salt, prodrug, or stereoisomer thereof.
[0167] Table 1.
[0168]
[0169] In some embodiments, the cationic lipid is a cationic lipid described in International Patent Application No. PCT / CN2022 / 072694, the entire text of which is incorporated herein by reference. In some embodiments, the cationic lipid is a compound of formula (02-I):
[0170]
[0171] or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, wherein:
[0172] G 1 and G 2 Each independently is C2-C 12 Alkylene or C2-C 12 Alkenylene, where G 1 and G 2 One or more -CH2- in is optionally replaced by -O-, -C(=O)O- or -OC(=O)-;
[0173] Each L 1 Independently -OC(=O)R 1 、-C(=O)OR 1 、-OC(=O)OR 1 、-C(=O)R 1 、-OR 1 、-S(O) x R 1 、-S-SR 1 、-C(=O)SR 1 、-SC(=O)R 1 、-NR a C(=O)R 1 、-C(=O)NR b R c 、-NR a C(=O)NR b R c 、-OC(=O)NR b R c 、-NR a C(=O)OR 1 、-SC(=S)R 1 、-C(=S)SR 1 、-C(=S)R 1 、-CH(OH)R 1 、-P(=O)(OR b )(OR c ),-NR a P(=O)(OR b )(OR c );
[0174] Each L 2 Independently -OC(=O)R 2 、-C(=O)OR 2 、-OC(=O)OR 2 、-C(=O)R 2 、-OR 2 、-S(O) x R 2 、-S-SR 2 、-C(=O)SR 2 、-SC(=O)R 2 、-NR d C(=O)R 2 、-C(=O)NR e R f 、-NR d C(=O)NR e R f 、-OC(=O)NR e R f 、-NR d C(=O)OR 2 、-SC(=S)R 2 、-C(=S)SR 2 、-C(=S)R 2 、-CH(OH)R 2 、-P(=O)(OR e )(OR f ),-NR d P(=O)(OR e )(OR f );
[0175] R 1 and R 2 Each independently is C6-C 24 Alkyl or C6-C 24 alkenyl;
[0176] R a , R b , R d and R e Each independently is H, C1-C 24 Alkyl or C2-C 24 alkenyl;
[0177] R c and R f Each independently is C1-C 24 Alkyl or C2-C 24 alkenyl;
[0178] G 3C2-C 12 Alkylene or C2-C 12 Alkenylene, wherein part or all of the alkylene or alkenylene groups are optionally replaced by C3-C8 cycloalkylene or C3-C8 cycloalkenylene;
[0179] R 3 -N(R 4 )R 5 、-OR 6 or -SR 6 ;
[0180] R 4 C1-C 12 Alkyl, C2-C 12 C3-C8 cycloalkyl, C3-C8 cycloalkenyl, C6-C 10 Aryl or 4- to 8-membered heterocycloalkyl;
[0181] R 5 H, C1-C 12 Alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, C6-C 10 Aryl or 4- to 8-membered heterocycloalkyl;
[0182] R 6 is hydrogen, C1-C 12 Alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl or C6-C 10 Aryl;
[0183] x is 0, 1, or 2; and
[0184] wherein each alkyl, alkenyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl, alkylene, alkenylene, cycloalkylene, and cycloalkenylene is independently optionally substituted.
[0185] In some embodiments, the cationic lipid is a compound of formula (02-II):
[0186]
[0187] or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, wherein:
[0188] G 1 and G 2 Each independently is C2-C 12 Alkylene or C2-C 12 Alkenylene, where G 1 and G 2 One or more -CH2- in is optionally replaced by -O-, -C(=O)O- or -OC(=O)-;
[0189] Each L 1independently is –OC(=O)R 1 、-C(=O)OR 1 、-OC(=O)OR 1 、-C(=O)R 1 、-OR 1 、-S(O) x R 1 、-S-SR 1 、-C(=O)SR 1 、-SC(=O)R 1 、-NR a C(=O)R 1 、-C(=O)NR b R c 、-NR a C(=O)NR b R c 、-OC(=O)NR b R c 、-NR a C(=O)OR 1 、-SC(=S)R 1 、-C(=S)SR 1 、-C(=S)R 1 、-CH(OH)R 1 、-P(=O)(OR b )(OR c )、-NR a P(=O)(OR b )(OR c );
[0190] Each L 2 independently is –OC(=O)R 2 、-C(=O)OR 2 、-OC(=O)OR 2 、-C(=O)R 2 、-OR 2 、-S(O) x R 2 、-S-SR 2 、-C(=O)SR 2 、-SC(=O)R 2 、-NR d C(=O)R 2 、-C(=O)NR e R f 、-NR d C(=O)NR e R f 、-OC(=O)NR e R f 、-NRd C(=O)OR 2 、-SC(=S)R 2 、-C(=S)SR 2 、-C(=S)R 2 、-CH(OH)R 2 、-P(=O)(OR e )(OR f ),-NR d P(=O)(OR e )(OR f );
[0191] R 1 and R 2 Each independently is C6-C 24 Alkyl or C6-C 24 alkenyl;
[0192] R a , R b , R d and R e Each independently is H, C1-C 24 Alkyl or C2-C 24 alkenyl;
[0193] R c and R f Each independently is C1-C 24 Alkyl or C2-C 24 alkenyl;
[0194] G 3 C2-C 12 Alkylene or C2-C 12 Alkenylene, wherein part or all of the alkylene or alkenylene groups are optionally replaced by C3-C8 cycloalkylene or C3-C8 cycloalkenylene;
[0195] R 3 -N(R 4 )R 5 、-OR 6 or -SR 6 ;
[0196] R 4 C1-C 12 Alkyl, C2-C 12 C3-C8 cycloalkyl, C3-C8 cycloalkenyl, C6-C 10 Aryl or 4- to 8-membered heterocycloalkyl;
[0197] R 5 H, C1-C 12 Alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, C6-C10 Aryl or 4- to 8-membered heterocycloalkyl;
[0198] R 6 is hydrogen, C1-C 12 Alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl or C6-C 10 Aryl;
[0199] x is 0, 1, or 2; and
[0200] wherein each alkyl, alkenyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl, alkylene, alkenylene, cycloalkylene, and cycloalkenylene is independently optionally substituted.
[0201] In some embodiments, the compound is of formula (02-VA), (02-VB), (02-VC), (02-VD), (02-VE), (02-VF):
[0202]
[0203] wherein z is an integer from 2 to 12,
[0204] x0 is an integer from 1 to 11;
[0205] y0 is an integer from 1 to 11;
[0206] x1 is an integer from 0 to 9;
[0207] y1 is an integer from 0 to 9;
[0208] x2 is an integer from 2 to 9;
[0209] x3 is an integer from 1 to 5;
[0210] x4 is an integer from 0 to 3;
[0211] y2 is an integer from 2 to 9;
[0212] y3 is an integer from 1 to 5; and
[0213] y4 is an integer from 0 to 3;
[0214] or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof.
[0215] In some embodiments, z is an integer from 2 to 6. In some embodiments, z is 2, 4 or 5. In some embodiments, x0 and y0 are independently 2 to 6. In some embodiments, x0 and y0 are independently 4 or 5. In some embodiments, x1 and y1 are independently 2 to 6. In some embodiments, x1 and y1 are independently 4 or 5. In some embodiments, x2 and y2 are independently an integer from 2 to 8. In some embodiments, x2 and y2 are independently 3, 5 or 7. In some embodiments, x3 and y3 are both 1. In some embodiments, x4 and y4 are independently 0 or 1.
[0216] In some embodiments, each L 1 Independently -OR 1 、-OC(=O)R 1 OR -C(=O)OR 1 , and each L 2 Independently for –OR 2 、-OC(=O)R 2 OR -C(=O)OR 2 In some embodiments, R 1 and R 2 Independently straight chain C6-C 10 Alkyl or -R 7 -CH(R 8 )(R 9 ), where R 7 is C0-C5 alkylene, and R 8 and R 9 Independently for C2-C 10 Alkyl or C2-C 10 Alkenyl.
[0217] In some embodiments, the compound is a compound of formula (02-VI-A), (02-VI-B), (02-VI-C), (02-VI-D), (02-VI-E), or (02-VI-F):
[0218]
[0219] wherein z is an integer from 2 to 12;
[0220] y is an integer from 2 to 12;
[0221] x0 is an integer from 1 to 11;
[0222] x1 is an integer from 0 to 9;
[0223] x2 is an integer from 2 to 5;
[0224] x3 is an integer from 1 to 5; and
[0225] x4 is an integer from 0 to 3;
[0226] or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof.
[0227] In some embodiments, z is an integer from 2 to 6. In some embodiments, z is 2, 4, or 5. In some embodiments, x0 is 4 or 5. In some embodiments, x1 is 4 or 5. In some embodiments, x2 is an integer from 2 to 5. In some embodiments, x2 is 3 or 5. In some embodiments, x3 is 0 or 1. In some embodiments, y is an integer from 2 to 6. In some embodiments, y is 5.
[0228] In some embodiments, each L 1 Independently -OR 1 、-OC(=O)R 1 OR -C(=O)OR 1 , and L 2 -OC(=O)R 2 OR -C(=O)OR 2 、-NR d C(=O)R 2 or -C(=O)NR e R f In some embodiments, R 1 Straight chain C6-C 10 Alkyl or -R 7 -CH(R 8 )(R 9 ), where R 7 is C0-C5 alkylene, and R 8 and R 9 Independently for C2-C 10 Alkyl or C2-C 10 In some embodiments, R 2 and R f Each independently is a straight chain C6-C 18 Alkyl, C6-C 18 Alkenyl or -R 7 -CH(R 8 )(R 9 ), where R 7 is C0-C5 alkylene, and R 8 and R 9 Independently for C2-C 10 Alkyl or C2-C 10 In some embodiments, R d and R e Each is independently H.
[0229] In some embodiments, the compound is a compound in Table 2 or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof.
[0230] Table 2.
[0231]
[0232]
[0233] In some embodiments, the cationic lipid described herein is a cationic lipid described in International Patent Publication No. WO 2022 / 152109, which is incorporated herein by reference in its entirety.
[0234] In some embodiments, the cationic lipid is a compound of formula (03-I):
[0235]
[0236] or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, wherein:
[0237] G 1 and G 2 Each independently is a bond, C2-C 12 Alkylene or C2-C 12 Alkenylene, where G 1 and G 2 One or more -CH2- in are optionally replaced by -O-;
[0238] Each L 1 Independently -OC(=O)R 1 、-C(=O)OR 1 、-OC(=O)OR 1 、-C(=O)R 1 、-OR 1 、-S(O) x R 1 、-S-SR 1 、-C(=O)SR 1 、-SC(=O)R 1 、-NR a C(=O)R 1 、-C(=O)NR b R c 、-NR a C(=O)NR b R c 、-OC(=O)NR b R c 、-NR a C(=O)OR 1、-SC(=S)R 1 、-C(=S)SR 1 、-C(=S)R 1 、-CH(OH)R 1 、-P(=O)(OR b )(OR c ),-NR a P(=O)(OR b )(OR c )、-(C6-C 10 Arylene)-R 1 , -(6- to 10-membered heteroarylene)-R 1 、-(4- to 8-membered heterocyclylene)-R 1 or R 1 ;
[0239] Each L 2 Independently -OC(=O)R 2 、-C(=O)OR 2 、-OC(=O)OR 2 、-C(=O)R 2 、-OR 2 、-S(O) x R 2 、-S-SR 2 、-C(=O)SR 2 、-SC(=O)R 2 、-NR d C(=O)R 2 、-C(=O)NR e R f 、-NR d C(=O)NR e R f 、-OC(=O)NR e R f 、-NR d C(=O)OR 2 、-SC(=S)R 2 、-C(=S)SR 2 、-C(=S)R 2 、-CH(OH)R 2 、-P(=O)(OR e )(OR f ),-NR d P(=O)(OR e )(OR f )、-(C6-C 10 Arylene)-R 2 , -(6- to 10-membered heteroarylene)-R 2、-(4- to 8-membered heterocyclylene)-R 2 or R 2 ;
[0240] R 1 and R 2 Each independently is C6-C 24 Alkyl or C6-C 24 alkenyl;
[0241] R a , R b , R d and R e Each independently is H, C1-C 24 Alkyl or C2-C 24 alkenyl;
[0242] R c and R f Each independently is C1-C 24 Alkyl or C2-C 24 alkenyl;
[0243] G 3 C2-C 12 Alkylene or C2-C 12 Alkenylene, wherein some or all of the alkylene or alkenylene groups are optionally replaced by: C3-C8 cycloalkylene, C3-C8 cycloalkenylene, C3-C8 cycloalkynylene, 4 to 8 membered heterocyclylene, C6-C 10 an arylene group or a 5- to 10-membered heteroarylene group;
[0244] R 3 is hydrogen, C1-C 12 Alkyl, C2-C 12 Alkenyl, C2-C 12 Alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, C3-C8 cycloalkynyl, 4- to 8-membered heterocyclic group, C6-C 10 aryl or 5- to 10-membered heteroaryl; or R 3 and G 1 or G 1 A portion of R together with the nitrogen to which it is attached forms a cyclic portion; or R 3 and G 3 or G 3 A portion of forms a cyclic portion together with the nitrogen to which it is attached;
[0245] R 4 C1-C 12 Alkyl or C3-C8 cycloalkyl;
[0246] x is 0, 1, or 2;
[0247] n is 1 or 2;
[0248] m is 1 or 2; and
[0249] wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, heterocyclyl, aryl, heteroaryl, alkylene, alkenylene, cycloalkylene, cycloalkenylene, cycloalkynylene, heterocyclylene, arylene, heteroarylene, and cyclic moiety is independently optionally substituted.
[0250] In some embodiments, the cationic lipid is a compound of formula (03-II-A):
[0251]
[0252] or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof.
[0253] In some embodiments, the cationic lipid is a compound of formula (03-II-B):
[0254]
[0255] or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof.
[0256] In some embodiments, the cationic lipid is a compound of formula (03-II-C):
[0257]
[0258] or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof.
[0259] In some embodiments, the cationic lipid is a compound of formula (03-II-D):
[0260]
[0261] or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof.
[0262] In some embodiments, G 1 and G 2 Each independently is C2-C 12 In some embodiments, G 1 and G 2 Each is independently C5 alkylene. 3 It is a C2-C6 alkylene group.
[0263] In some embodiments, R 3 C1-C 12 Alkyl, C2-C 12 In some embodiments, R 3is a C3-C8 cycloalkyl group. 3 In some embodiments, R 4 For the replacement of C1-C 12 In some embodiments, R 4 is –CH2CH2OH.
[0264] In some embodiments, L 1 =–OC(=O)R 1 、-C(=O)OR 1 、-NR a C(=O)R 1 or -C(=O)NR b R c ; and L 2 =–OC(=O)R 2 、-C(=O)OR 2 、-NR d C(=O)R 2 or -C(=O)NR e R f In some embodiments, R 1 , R 2 , R c and R f Each independently is a straight chain C6-C 18 Alkyl, straight chain C6-C 18 Alkenyl or -R 7 -CH(R 8 )(R 9 ), where R 7 is C0-C5 alkylene, and R 8 and R 9 Independently for C2-C 10 Alkyl or C2-C 10 In some embodiments, R 1 , R 2 , R c and R f Each independently is a straight chain C7-C 15 Alkyl, straight chain C7-C 15 Alkenyl or -R 7 -CH(R 8 )(R 9 ), where R 7 is C0-C1 alkylene, and R 8 and R 9 are independently C4-C8 alkyl or C6-C 10 In some embodiments, R a , R b , R dand R e Each is independently H.
[0265] In some embodiments, the cationic lipid is a compound in Table 3 or a pharmaceutically acceptable salt, prodrug, or stereoisomer thereof.
[0266] Table 3
[0267]
[0268] In some embodiments, the cationic lipid is a cationic lipid described in International Patent Application No. PCT / CN2022 / 094227, which is incorporated herein by reference in its entirety.
[0269] In some embodiments, the cationic lipid is a compound of formula (04-I):
[0270]
[0271] or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, wherein:
[0272] G 1 and G 2 Each independently is a bond, C2-C 12 Alkylene or C2-C 12 alkenylene;
[0273] L 1 = –OC(=O)R 1 、-C(=O)OR 1 、-OC(=O)OR 1 、-C(=O)R 1 、-OR 1 、-S(O) x R 1 、-S-SR 1 、-C(=O)SR 1 、-SC(=O)R 1 、-NR a C(=O)R 1 、-C(=O)NR b R c 、-NR a C(=O)NR b R c 、-OC(=O)NR b R c 、-NR a C(=O)OR 1 、-SC(=S)R 1 、-C(=S)SR 1 、-C(=S)R1 、-CH(OH)R 1 、-P(=O)(OR b )(OR c )、-(C6-C 10 Arylene)-R 1 , -(6- to 10-membered heteroarylene)-R 1 or R 1 ;
[0274] L 2 = –OC(=O)R 2 、-C(=O)OR 2 、-OC(=O)OR 2 、-C(=O)R 2 、-OR 2 、-S(O) x R 2 、-S-SR 2 、-C(=O)SR 2 、-SC(=O)R 2 、-NR d C(=O)R 2 、-C(=O)NR e R f 、-NR d C(=O)NR e R f 、-OC(=O)NR e R f 、-NR d C(=O)OR 2 、-SC(=S)R 2 、-C(=S)SR 2 、-C(=S)R 2 、-CH(OH)R 2 、-P(=O)(OR e )(OR f )、-(C6-C 10 Arylene)-R 2 , -(6- to 10-membered heteroarylene)-R 2 or R 2 ;
[0275] R 1 and R 2 Each independently is C5-C 32 Alkyl or C5-C 32 alkenyl;
[0276] R a , R b , R d and R eEach independently is H, C1-C 24 Alkyl or C2-C 24 alkenyl;
[0277] R c and R f Each independently is C1-C 32 Alkyl or C2-C 32 alkenyl;
[0278] R 0 C1-C 12 Alkyl, C2-C 12 C3-C8 cycloalkyl, C3-C8 cycloalkenyl, C6-C 10 Aryl or 4- to 8-membered heterocycloalkyl;
[0279] G 3 C2-C 12 Alkylene or C2-C 12 alkenylene;
[0280] R 4 C1-C 12 Alkyl, C2-C 12 C3-C8 cycloalkyl, C3-C8 cycloalkenyl, C6-C 10 Aryl or 4- to 8-membered heterocycloalkyl;
[0281] R 5 C1-C 12 Alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, C6-C 10 Aryl or 4- to 8-membered heterocycloalkyl;
[0282] x is 0, 1, or 2;
[0283] s is 0 or 1; and
[0284] wherein each alkyl, alkenyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl, alkylene, alkenylene, arylene and heteroarylene is independently optionally substituted.
[0285] In some embodiments, the cationic lipid is a compound of formula (04-III):
[0286]
[0287] or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, wherein:
[0288] R 1 and R 2 Each independently is C5-C 32 Alkyl or C5-C 32 alkenyl;
[0289] R 0 C1-C 12 Alkyl, C2-C 12 C3-C8 cycloalkyl, C3-C8 cycloalkenyl, C6-C 10 Aryl or 4- to 8-membered heterocycloalkyl;
[0290] G 3 C2-C 12 Alkylene or C2-C 12 alkenylene;
[0291] G 4 C2-C 12 Alkylene or C2-C 12 alkenylene;
[0292] R 3 -N(R 4 )R 5 OR 6 ;
[0293] R 4 C1-C 12 Alkyl, C2-C 12 C3-C8 cycloalkyl, C3-C8 cycloalkenyl, C6-C 10 Aryl or 4- to 8-membered heterocycloalkyl;
[0294] R 5 C1-C 12 Alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, C6-C 10 Aryl or 4- to 8-membered heterocycloalkyl; or R 4 and R 5 Together with the nitrogen to which it is attached, it forms a cyclic portion;
[0295] R 6 is hydrogen, C1-C 12 Alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkenyl or C6-C 10 aryl; and
[0296] wherein each alkyl, alkenyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl, alkylene, alkenylene and cyclic moiety is independently optionally substituted.
[0297] In some embodiments, the cationic lipid is a compound of formula (04-IV):
[0298]
[0299] or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof.
[0300] In some embodiments, G 3 is C2-C4 alkylene. 4 It is a C2-C4 alkylene group.
[0301] In some embodiments, R 0 is C1-C6 alkyl. 3 In some embodiments, R 3 -N(R 4 )R 5 In some embodiments, R 4 is a C3-C8 cycloalkyl group. 4 In some embodiments, R 5 It is -CH2CH2OH.
[0302] In some embodiments, L 1 = –OC(=O)R 1 、-C(=O)OR 1 、-C(=O)R 1 、-C(=O)NR b R c or R 1 ; and L 2 = –OC(=O)R 2 、-C(=O)OR 2 、-C(=O)R 2 、-C(=O)NR e R f or R 2 In some embodiments, R 1 and R 2 Each independently is a branched chain C6-C 24 Alkyl or branched chain C6-C 24 In some embodiments, R 1 and R 2 Each independently is -R 7 -CH(R 8 )(R 9 ), where R 7 is C1-C5 alkylene, and R 8 and R 9 Independently for C2-C 10 Alkyl or C2-C 10 In some embodiments, R 1 Straight chain C6-C 24 Alkyl and R 2 Branched chain C6-C 24 In some embodiments, R 1Straight chain C6-C 24 Alkyl and R 2 For-R 7 -CH(R 8 )(R 9 ), where R 7 is C1-C5 alkylene, and R 8 and R 9 Independently for C2-C 10 alkyl.
[0303] In some embodiments, the cationic lipid is a compound in Table 4 or a pharmaceutically acceptable salt, prodrug, or stereoisomer thereof.
[0304] Table 4.
[0305]
[0306] In some embodiments, the cationic lipid contained in the particles or compositions provided herein is a cationic lipid described in US Pat. Nos. US10442756B2, US9868691B2, or US9868692B2, all of which are incorporated herein by reference.
[0307] In some embodiments, the cationic lipid is a compound of formula (05-I):
[0308]
[0309] or a salt or isomer thereof, wherein
[0310] l is selected from 1, 2, 3, 4 and 5;
[0311] m is selected from 5, 6, 7, 8 and 9;
[0312] M1 is a bond or M';
[0313] R 4 is an unsubstituted C1-C3 alkyl or -(CH2) n OH, -NHC(S)N(R)2, -NHC(O)N(R)2, -N(R)C(O)R, -N(R)S(O)2R, -N(R)R8, -NHC(=NR9)N(R)2, -NHC(=CHR9)N(R)2, -OC(O)N(R)2, -N(R)C(O)OR, -N(OR) C(O)R, -N(OR)S(O)2R, -N(OR)C(O)OR, -N(OR)C(O)N(R)2, -N(OR)C(S)N(R)2, -N(OR)C(=NR9)N(R)2, -N(OR)C(=CHR9)N(R)2 or heteroaryl, and each n is selected from 1, 2, 3, 4 or 5;
[0314] M and M' are independently selected from -C(O)O-, -OC(O)-, -C(O)N(R')-, -P(O)(OR')O-, -SS-, aryl, and heteroaryl; and
[0315] R2 and R3 are both C1-C 14 Alkyl or C2-C 14 Alkenyl,
[0316] R8 is selected from the group consisting of C3-C6 carbocyclic ring and heterocyclic ring;
[0317] R9 is selected from the group consisting of H, CN, NO2, C1-C6 alkyl, -OR, -S(O)2R, -S(O)2N(R)2, C2-C6 alkenyl, C3-C6 carbocycle and heterocycle;
[0318] Each R is independently selected from the group consisting of C1-C3 alkyl, C2-C3 alkenyl, and H; and
[0319] R' is a straight chain alkyl group.
[0320] In some embodiments, the cationic lipid is SM102 or lipid 5:
[0321]
[0322]
[0323] In some embodiments, the cationic lipid is a cationic lipid described in US Pat. No. US10166298B2, the entire teachings of which are incorporated herein by reference.
[0324] In some embodiments, the cationic lipid is a compound of formula (06-I):
[0325]
[0326] or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein:
[0327] L 1 or L 2 One of them is -O(C═O)-, -(C═O)O-, -C(═O)-, -O-, -S(O) x -, -SS-, -C(═O)S-, SC(═O)-, -NR a C(═O)-、-C(═O)NR a -、NR a C(═O)NR a -、-OC(═O)NRa -or-NR a C(═O)O-, and L 1 or L 2 The other is -O(C═O)-, -(C═O)O-, -C(═O)-, -O-, -S(O) x -, -SS-, -C(═O)S-, SC(═O)-, -NR a C(═O)-、-C(═O)NR a -、NR a C(═O)NR a -、-OC(═O)NR a -or-NR a C(═O)O- or direct bond;
[0328] G 1 and G 2 Each is independently unsubstituted C1-C 12 Alkylene or C1-C 12 alkenylene;
[0329] G 3 C1-C 24 Alkylene, C1-C 24 Alkenylene, C3-C8 cycloalkylene, C3-C8 cycloalkenylene;
[0330] R a H or C1-C 12 alkyl;
[0331] R 1 and R 2 Each independently is C6-C 24 Alkyl or C6-C 24 alkenyl;
[0332] R 3 H, OR 5 、CN、-C(=O)OR 4 、-OC(=O)R 4 or -NR 5 C(=O)R 4 ;
[0333] R 4 C1-C 12 alkyl;
[0334] R 5 is H or C1-C6 alkyl; and
[0335] x is 0, 1, or 2.
[0336] In some embodiments, the cationic lipid is a compound of Table 5 or a pharmaceutically acceptable salt, prodrug, or stereoisomer thereof.
[0337] Table 5.
[0338]
[0339] In some embodiments, the cationic lipids of the present disclosure are the same as those disclosed in International Application Publication No. WO 2010 / 144740, all teachings of which are incorporated herein by reference. For example, the cationic lipid is a compound represented by formula (07-I), also referred to as compound 07-I:
[0340]
[0341] Preferably, the ionizable lipids used in the LNP according to the present invention are selected from:
[0342] Compound of formula (01-10):
[0343]
[0344] wherein y and z are each independently an integer from 4 to 6,
[0345] s is an integer from 2 to 4,
[0346] t is an integer from 1 to 3, and
[0347] R 1 and R 2 Each independently is C 12 -C 22 alkyl;
[0348] R 4 is a C3-C8 cycloalkyl group;
[0349] R 6 is hydrogen or hydroxyl,
[0350] Compound of formula 05-I:
[0351]
[0352] in
[0353] l is selected from 1, 2, 3, 4 and 5;
[0354] m is selected from 5, 6, 7, 8 and 9;
[0355] M1 is -C(O)O-;
[0356] R4 is -(CH2) nOH, and n is selected from 1, 2, 3, 4 or 5;
[0357] M is -OC(O)-; and
[0358] R2 and R3 are both C 6-10 alkyl,
[0359] Compound of formula (06-1):
[0360]
[0361] in
[0362] L 1 and L 2 is -O(C═O)-;
[0363] G 1 and G 2 Each is independently an unsubstituted C4-C8 alkylene group;
[0364] G 3 is C3-C8 alkylene;
[0365] R 1 and R 2 Each independently is C 12 -C 22 alkyl;
[0366] R 3 is H or OH,
[0367] Compound of formula (02-VB)
[0368]
[0369] in
[0370] Each L 1 Independently -OC(=O)R 1 ;
[0371] Each L 2 Independently -OC(=O)R 2 ;
[0372] R 1 and R 2 Each independently is C6-C 24 alkyl;
[0373] R 3 For-OR 6 ;
[0374] R 6 is hydrogen;
[0375] z is an integer from 2 to 12;
[0376] x1 is an integer from 0 to 9;
[0377] y1 is an integer from 0 to 9;
[0378] Compound of formula (02-VI-F)
[0379]
[0380] in
[0381] Each L 1 Independently -OC(=O)R 1 ;
[0382] Each L 2 Independently -OC(=O)R 2 ;
[0383] R 1 and R 2 Each independently is C6-C 24 Alkyl or C6-C 24 alkenyl;
[0384] R 3 For-OR 6 ;
[0385] R 6 is hydrogen;
[0386] z is an integer from 2 to 12;
[0387] y is an integer from 2 to 12;
[0388] x1 is an integer from 2 to 5;
[0389] Compound of formula (02-VF)
[0390]
[0391] in
[0392] Each L 1 Independently -OC(=O)R 1 ;
[0393] Each L 2 Independently -OC(=O)R 2 ;
[0394] R 1 and R 2 Each independently is C6-C 24 alkyl;
[0395] R 3 For-OR 6;
[0396] R 6 is hydrogen;
[0397] z is an integer from 2 to 12;
[0398] x2 is an integer from 2 to 9;
[0399] x4 is an integer from 0 to 3;
[0400] y2 is an integer from 2 to 9;
[0401] y4 is an integer from 0 to 3,
[0402] Compound of formula (03-I)
[0403]
[0404] in
[0405] G 1 and G 2 Each is independently C3-C8 alkylene;
[0406] Each L 1 Independently -OC(=O)R 1 OR -C(=O)OR 1 ;
[0407] Each L 2 are independently -C(=O)OR 2 or –OC(=O)R 2 ;
[0408] R 1 Independently C6-C 24 alkyl;
[0409] R 2 Independently C6-C 24 alkyl;
[0410] G 3 C2-C 12 Alkylene;
[0411] R 3 is a C3-C8 cycloalkyl group;
[0412] R 4 is C1-C4 hydroxyalkyl;
[0413] n is 1 or 2;
[0414] m is 1 or 2, and
[0415] Compound 07-I:
[0416]
[0417] More preferably, the ionizable lipids used in the LNP according to the present invention are selected from the following compounds:
[0418]
[0419]
[0420]
[0421] as well as
[0422]
[0423] C. Polymer-bound lipids
[0424] In some embodiments, LNP comprises polymer-bound lipid.Polymers that can be incorporated into polymer-bound lipid include polyamines, polyethers, polyamides, polyesters, polyurethanes, polyureas, polycarbonates, polystyrenes, polyimides, polysulfones, polyurethanes, polyacetylene, polyethylene, polyethyleneimine, polyisocyanates, polyacrylates, polymethacrylates, polyacrylonitrile and polyarylates. For example, the polymer may include poly(caprolactone) (PCL), ethylene vinyl acetate polymer (EVA), poly(lactic acid) (PLA), poly(L-lactic acid) (PLLA), poly(glycolic acid) (PGA), poly(lactic acid-co-glycolic acid) (PLGA), poly(L-lactic acid-co-glycolic acid) (PLLGA), poly(D,L-lactide) (PDLA), poly(L-lactide) (PLLA), poly(D,L-lactide-co-caprolactone), poly(D,L-lactide-co-caprolactone-co-glycolide), poly(D,L-lactide-co-PEO), or poly(D,L-lactide-co-caprolactone). ,L-lactide), poly(D,L-lactide-co-PPO-co-D,L-lactide), polyalkyl cyanoacrylates, polyurethanes, poly-L-lysine (PLL), hydroxypropyl methacrylate (HPMA), polyethylene glycol, poly-L-glutamic acid, poly(hydroxy acids), polyanhydrides, polyorthoesters, poly(esteramides), polyamides, poly(etheresters), polycarbonates, polyolefins such as polyethylene and polypropylene, polyglycols such as poly(ethylene glycol) (PEG), polyoxyalkylenes (PEO), polyalkylene terephthalates such as poly(ethylene terephthalate), polyvinyl alcohol (PVA), polyethylene ethers, polyvinyl esters such as poly(vinyl acetate)), polyvinyl halides such as poly(vinyl chloride) (PVC), polyvinyl pyrrolidone, polysiloxanes, polystyrene (PS), polyurethanes, derivatized celluloses such as alkyl celluloses, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitrocellulose, hydroxypropyl cellulose, carboxymethyl cellulose, acrylic polymers such as poly(methyl (meth) acrylate) (PMMA), poly(ethyl (meth) acrylate), poly(butyl (meth) acrylate), poly(isobutyl (meth) acrylate), poly(hexyl (meth) acrylate), poly (isodecyl (meth)acrylate), poly(lauryl (meth)acrylate), poly(phenyl (meth)acrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecyl acrylate) and copolymers and mixtures thereof), polydioxanone and copolymers thereof, polyhydroxyalkanoate, polypropylene fumarate, polyoxymethylene, poloxamer, polyoxamine, poly(o-)esters, poly(butyric acid), poly(valeric acid), poly(lactide-co-caprolactone), trimethylene carbonate or polyvinylpyrrolidone.
[0425] In some embodiments, the polymer-bound lipid is a PEGylated lipid (PEG lipid). Without being bound by theory, it is expected that the polymer-bound lipid component in LNP can improve the colloidal stability of nanoparticles and / or reduce protein absorption. The exemplary PEGylated lipid that can be used in conjunction with the present disclosure includes but is not limited to PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, PEG-modified dialkylglycerol and their mixture. In some embodiments, the PEG-bound lipid can be PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol or PEG-modified dialkylglycerol. In some embodiments, the PEG lipid can be PEG-c-DOMG, PEG-DMG, PEG-DLPE, PEG-DMPE, PEG-DPPC, PEG-DSPE, ceramide-PEG2000 or Chol-PEG2000.
[0426] In some embodiments, the pegylated lipid is a pegylated diacylglycerol (PEG-DAG) such as 1-(monomethoxy-polyethylene glycol)-2,3-dimyristoylglycerol (PEG-DMG), a pegylated phosphatidylethanolamine (PEG-PE), a PEG succinate diacylglycerol (PEG-S-DAG) such as 4-O-(2',3'-di(tetradecanoyloxy)propyl-1-O-(ω-methoxy(polyethoxy)ethyl)succinate (PEG-S-DMG)), a pegylated ceramide (PEG-cer), or a PEG dialkoxypropyl carbamate such as ω-methoxy(polyethoxy)ethyl-N-(2,3-di(tetradecanoyl)propyl)carbamate or 2,3-di(tetradecanoyl)propyl-N-(ω-methoxy(polyethoxy)ethyl)carbamate.
[0427] In some embodiments, the PEGylated lipid is present at a concentration in the range of 1.0 to 2.5 molar percent. In some embodiments, the polymer-bound lipid is present at a concentration of about 1.7 molar percent. In some embodiments, the polymer-bound lipid is present at a concentration of about 1.5 molar percent.
[0428] In some embodiments, the molar ratio of ionizable lipid to polymer-bound lipid is in the range of about 20: 1 to about 100: 1. In some embodiments, the molar ratio of ionizable lipid to polymer-bound lipid is in the range of about 25: 1 to about 80: 1. In some embodiments, the molar ratio of ionizable lipid to polymer-bound lipid is in the range of about 30: 1 to about 60: 1. In some embodiments, the molar ratio of ionizable lipid to polymer-bound lipid is in the range of about 30: 1 to about 50: 1.
[0429] In some embodiments, the PEGylated lipid has the following structural formula:
[0430]
[0431] or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
[0432] R 12 and R 13 Each is independently a straight or branched alkyl or alkenyl chain containing from 10 to 30 carbon atoms, wherein the alkyl chain is optionally interrupted by one or more ester bonds; and
[0433] w has an average value in the range of 30 to 60.
[0434] In some embodiments, R 12 and R 13 Each independently is a linear saturated alkyl chain containing 12 to 16 carbon atoms. In other embodiments, the average w is in the range of 42 to 55, for example, the average w is 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54 or 55. In some embodiments, the average w is about 49.
[0435] In some embodiments, the PEGylated lipid has the following structural formula:
[0436]
[0437] or a pharmaceutical salt thereof, wherein the average w is about 49.
[0438] D. Lipid Stabilizer
[0439] In some embodiments, LNP comprises lipid stabilizer. In some embodiments, lipid stabilizer comprises sterol. In some embodiments, lipid stabilizer comprises corticosteroid. In some embodiments, lipid stabilizer comprises two or more components. In some embodiments, lipid stabilizer comprises corticosteroid and sterol. In some embodiments, sterol is selected from the group consisting of: cholesterol, coprosterol, sitosterol, ergosterol, campesterol, stigmasterol and rapeseed sterol. In some embodiments, corticosteroid is selected from the group consisting of: prednisolone, dexamethasone, prednisone and hydrocortisone. In some embodiments, lipid stabilizer comprises tomatine, tomatine, ursolic acid or alpha-tocopherol. In some embodiments, the lipid stabilizer comprises one or more compounds selected from the group consisting of cholesterol, coprosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, prednisolone, dexamethasone, prednisone, hydrocortisone, tomatine, lycopene, ursolic acid, and alpha-tocopherol. In some embodiments, the lipid stabilizer is cholesterol.
[0440] E. LNPs containing mRNA
[0441] In some embodiments, the LNP disclosed herein further comprises a therapeutic payload. The payload can be any substance or compound with a therapeutic or preventive effect. In some embodiments, the therapeutic payload is a small molecule, a cytotoxin, a radioactive ion, a chemotherapeutic compound, a vaccine, or a compound that induces an immune response.
[0442] In some embodiments, LNP disclosed herein comprises nucleic acid. In some embodiments, nucleic acid is DNA. In some embodiments, DNA is catalytic DNA, plasmid DNA, aptamer or complementary DNA (cDNA). In some embodiments, nucleic acid is RNA. In some embodiments, RNA is messenger RNA (mRNA), antisense oligonucleotide, micro RNA (miRNA), miRNA inhibitor (e.g., antagomir or antimir), messenger RNA interference complementary RNA (micRNA), multivalent RNA, dicer substrate RNA (dsRNA), small hairpin RNA (shRNA), antisense RNA, transfer RNA (tRNA), asymmetric interference RNA (aiRNA), ribozyme, aptamer or carrier. In some embodiments, RNA is mRNA hybrid. In some embodiments, nucleic acid is mRNA. In some embodiments, mRNA encodes protein. In some embodiments, protein is antibody. In some embodiments, antibody is bispecific antibody. In some embodiments, LNP comprises RNAi agent or RNAi inducer. Preferably, the weight ratio of ionizable lipid to therapeutic payload is 5: 1 to 20: 1.
[0443] F. Compositions containing lipid nanoparticles (LNPs)
[0444] The present disclosure includes compositions comprising LNP described herein. In some embodiments, the compositions include multiple LNPs. In some embodiments, multiple LNPs have a polydispersity index (PDI) of 0.001 to 0.2. In some embodiments, multiple LNPs have a polydispersity index (PDI) of 0.001 to 0.1. In some embodiments, LNPs have a PDI of 0.005 to 0.05.
[0445] In some embodiments, some of the LNPs of the LNP composition include mRNA. In some embodiments, the mRNA encapsulation efficiency (EE%-i.e., the percentage of individual LNPs encapsulating mRNA in the composition) of the LNP composition is 70% to 100%. In some embodiments, the EE% of the LNP composition is 80 to 95%. In some embodiments, the EE% of the LNP composition is 85 to 95%. In some embodiments, the EE% of the LNP composition is 90 to 95%. In some embodiments, the EE% is 80% or higher. In some embodiments, the EE% is 85% or higher. In some embodiments, the EE% is 90% or higher. In some embodiments, the EE% is 95% or higher. In some embodiments, the EE% is 80%-100%. In some embodiments, the EE% is 85%-100%. In some embodiments, the EE% is 90%-100%. In some embodiments, the EE% is 95%-100%.
[0446] In some embodiments, the LNP composition is capable of increasing protein expression compared to a similar LNP composition that does not include a steroid-containing phospholipid.
[0447] It should be understood that in any embodiment describing the composition of the LNP described herein, any of the mole percentages or mole ratios described above for the sterol-containing phospholipids, ionizable lipids, polymer-bound lipids, and lipid stabilizers can be combined with each other, such that each combination is contemplated as if each combination was specifically and individually disclosed.
[0448] G. Methods of preparing LNPs and compositions thereof
[0449] The LNPs herein can be prepared according to methods well known in the art.
[0450] In some embodiments, the method comprises dissolving the lipid components (e.g., phospholipids, ionizable lipids, polymer-bound lipids, and lipid stabilizers) in a solvent. In some embodiments, the method comprises the following steps:
[0451] (a) dissolving lipid components (e.g., phospholipids, ionizable lipids, polymer-bound lipids, and optionally a lipid stabilizer) in a solvent to produce a lipid mixture;
[0452] (b) diluting the mRNA in a solvent to produce an mRNA mixture; and
[0453] (c) The lipid mixture is mixed with the mRNA mixture to obtain the mRNA LNP mixture.
[0454] In some embodiments, the solvent in step (a) is a polar solvent. In some embodiments, the solvent in step (a) is an alcohol solvent. In some embodiments, the solvent in step (a) is methanol, ethanol, n-propanol or isopropanol. In some embodiments, the solvent in step (a) is ethanol.
[0455] In some embodiments, the solvent in step (b) is an aqueous solvent. In some embodiments, the solvent in step (b) is an aqueous buffer. In some embodiments, the solvent in step (b) is a citrate buffer. In some embodiments, the citrate buffer has a citrate concentration of 5 to 100mM. In some embodiments, the citrate buffer has a citrate concentration of 10 to 50mM. In some embodiments, the aqueous solvent of step (b) has a pH value of 2-6. In some embodiments, the aqueous solvent of step (b) has a pH value of 3-5.
[0456] In some embodiments, the mixing of step (c) is carried out with a lipid:mRNA weight ratio of 10:1 to 30:1. In some embodiments, the mixing of step (c) is carried out with a lipid:mRNA volume ratio of 1:1 to 1:5. In some embodiments, the volume ratio is 1:2 to 1:4. In some embodiments, the volume ratio is about 1:3. In some embodiments, the mixing of step (c) is carried out using a microfluidic device. In some embodiments, the microfluidic device has a flow rate of 9 to 30 mL / min.
[0457] In some embodiments, the mRNA mixture has an mRNA concentration of 1 to 3, 5, 7, 10, 12, 15, 20, 30, 40 or 50 mM. In some embodiments, the concentration is 3 to 5, 7, 10, 12, 15, 20 or 30 mM. In some embodiments, the concentration is 5 to 7, 10, 12, 15, 20 or 30 mM. In some embodiments, the concentration is 7 to 10, 12, 15, 20 or 30 mM. In some embodiments, the concentration is 10 to 12, 15, 20 or 30 mM. In some embodiments, the concentration is 12 to 15, 20 or 30 mM. In some embodiments, the concentration is 15 to 20 or 30 mM. In some embodiments, the concentration is 20 to 30 mM. In some embodiments, the concentration is about 5, 7, 10, 12, 15 or 20 mM. In some embodiments, the concentration is about 5, 7, 10, 12 or 15 mM. In some embodiments, the concentration is about 10 mM. In some embodiments, the concentration is about 12 mM. In some embodiments, the concentration is about 15 mM. In some embodiments, the concentration is about 20 mM.
[0458] In some embodiments, the method further comprises step (d):
[0459] (d) Filter the lipid nanoparticles through a sterile filter.
[0460] In some embodiments, the sterile filter is a 0.2 μm sterile filter.
[0461] IV. Methods Related to Lipid Nanoparticles (LNPs)
[0462] The present disclosure includes potentially useful methods of utilizing the LNPs described herein.
[0463] In some embodiments, a method is used to express a protein in a cell, wherein the method comprises introducing an LNP or a composition thereof as described above into a cell. In some embodiments, the cell is a mammalian cell. In some embodiments, the LNP or a composition thereof is administered systemically to a mammal. In some embodiments, the mammal is a human.
[0464] In some embodiments, the LNP composition is capable of increasing protein expression compared to a similar LNP composition that does not include a steroid-containing phospholipid.
[0465] V. Kits containing phospholipids containing sterol moieties
[0466] The present disclosure includes a kit comprising a phospholipid containing a sterol moiety and packaging of the phospholipid. In some embodiments, the kit further comprises an ionizable lipid. In some embodiments, the kit further comprises a polymer-bound lipid. In some embodiments, the kit further comprises a lipid stabilizer. In some embodiments, the kit further comprises an ionizable lipid, a polymer-bound lipid, and a lipid stabilizer. In some embodiments, the ionizable lipid is a cationic lipid. In some embodiments, the polymer-bound lipid is a pegylated lipid. In some embodiments, the lipid stabilizer is cholesterol. In some embodiments, the kit further comprises a cationic lipid, a pegylated lipid, and cholesterol.
[0467] It should be understood that any embodiment of the compound provided herein as set forth above and any specific substituent and / or variable of the compound provided herein as set forth above can be independently combined with other embodiments of the compound and / or substituent and / or variable to form an embodiment not specifically set forth above. In addition, in the case of listing the substituent and / or variable list of any specific group or variable, it should be understood that each individual substituent and / or variable can be deleted from a specific embodiment and / or technical solution, and the remaining substituent and / or variable list will be considered to be within the scope of the embodiment provided herein.
[0468] It is understood that throughout the specification, combinations of substituents and / or variables of the displayed formulas are permissible only if such contributions result in stable compounds.
[0469] Exemplary embodiments
[0470] The following exemplary embodiments are provided herein:
[0471] Embodiment 1. A lipid nanoparticle (LNP), comprising:
[0472] Phospholipids containing a sterol moiety;
[0473] Ionizable lipids; and
[0474] Polymer-bound lipids.
[0475] Embodiment 2. The LNP of embodiment 1, wherein the phospholipid has a structure selected from the group consisting of:
[0476]
[0477] as well as
[0478]
[0479] Embodiment 3. The LNP of embodiment 1 or 2, wherein the phospholipid has the following structure:
[0480]
[0481] Embodiment 4. The LNP of embodiment 1 or 2, wherein the phospholipid has the following structure:
[0482]
[0483] Embodiment 5. The LNP of any one of embodiments 1 to 4, wherein the LNP has a molar ratio of the ionizable lipid to the phospholipid of 20:1 to 2:1.
[0484] Embodiment 6. The LNP of embodiment 5, wherein the molar ratio of the ionizable lipid to the phospholipid is from 15:1 to 5:1.
[0485] Embodiment 7. The LNP of any one of embodiments 1 to 4, wherein the ionizable lipids account for 40 to 80 mol% of the total lipids in the LNP.
[0486] Embodiment 8. The LNP of embodiment 7, wherein the ionizable lipids account for 50 to 70 mol% of the total amount of lipids in the LNP.
[0487] Embodiment 9. The LNP of any one of embodiments 1 to 8, wherein the ionizable lipid is a cationic lipid.
[0488] Embodiment 10. The LNP of any one of embodiments 1 to 8, wherein the ionizable lipid is a compound according to any one of the formulas selected from 01-I, 01-II, 02-I, 02-II, 03-I, 03-II-A, 03-II-B, 03-II-C, 03-II-D, 04-I, 04-III, 04-IV, 05-I, 06-I, and subformulas thereof, or wherein the ionizable lipid is a cationic lipid selected from the compounds listed in any one of Tables 1 to 5.
[0489] Embodiment 11. The LNP of any one of embodiments 1 to 10, wherein the polymer-bound lipid accounts for 1 to 2% of the total lipid in the LNP.
[0490] Embodiment 12. The LNP of embodiment 11, wherein the polymer-bound lipids account for 1.5% of the total lipids in the LNP.
[0491] Embodiment 13. The LNP of any one of embodiments 1 to 12, wherein the LNP has a molar ratio of the polymer-bound lipid to the phospholipid of 1:5 to 1:10.
[0492] Embodiment 14. The LNP of any one of embodiments 1 to 13, wherein the polymer-bound lipid is a PEGylated lipid.
[0493] Embodiment 15. The LNP of any one of embodiments 1 to 13, wherein the polymer-bound lipid is a PEGylated lipid having the following structure:
[0494]
[0495] or a pharmaceutically acceptable salt thereof, wherein
[0496] R 12 and R 13 Each is independently a straight or branched alkyl or alkenyl chain containing from 10 to 30 carbon atoms, wherein the alkyl chain is optionally interrupted by one or more ester bonds; and
[0497] w is an integer in the range of 30 to 60.
[0498] Embodiment 16. The LNP of any one of embodiments 1 to 15, wherein the polymer-bound lipid is a PEGylated lipid having the following structure:
[0499]
[0500] or a pharmaceutically acceptable salt thereof, wherein
[0501] w is an integer in the range of 30 to 60.
[0502] Embodiment 17. The LNP of embodiment 15 or 16, wherein w is an integer in the range of 45 to 55.
[0503] Embodiment 18. The LNP of embodiment 15 or 16, wherein w is about 49.
[0504] Embodiment 19. The LNP of any one of embodiments 1 to 14, wherein the polymer-bound lipid is DMG-PEG or DMPE-PEG.
[0505] Embodiment 20. The LNP of any one of embodiments 1 to 19, further comprising a lipid stabilizer.
[0506] Embodiment 21. The LNP of embodiment 20, wherein the LNP has a molar ratio of the lipid stabilizer to the phospholipid of 10:1 to 1:4.
[0507] Embodiment 22. The LNP of embodiment 21, wherein the molar ratio of the lipid stabilizer to the phospholipid is 5:1 to 1:1.
[0508] Embodiment 23. The LNP of embodiment 21, wherein the molar ratio of the lipid stabilizer to the phospholipid is 4:1 to 3:1.
[0509] Embodiment 24. The LNP of any one of embodiments 20 to 23, wherein the lipid stabilizer accounts for 5 to 50 mol% of the total lipid in the LNP.
[0510] Embodiment 25. The LNP of embodiment 24, wherein the lipid stabilizer accounts for 8 to 40 mol% of the total amount of lipids in the LNP.
[0511] Embodiment 26. The LNP of embodiment 24, wherein the lipid stabilizer accounts for 10 to 30 mol% of the total amount of lipids in the LNP.
[0512] Embodiment 27. The LNP of any one of embodiments 1 to 26, wherein the phospholipids account for 1 to 30 mol% of the total lipids in the LNP.
[0513] Embodiment 28. The LNP of embodiment 27, wherein the phospholipids account for 2 to 25 mol% of the total amount of lipids in the LNP.
[0514] Embodiment 29. The LNP of embodiment 27, wherein the phospholipids account for 3 to 20 mol% of the total amount of lipids in the LNP.
[0515] Embodiment 30. The LNP of embodiment 27, wherein the phospholipids account for 5 to 15 mol% of the total amount of lipids in the LNP.
[0516] Embodiment 31. The LNP of embodiment 27, wherein the phospholipids account for about 10 mol% of the total amount of lipids in the LNP.
[0517] Embodiment 32. The LNP of any one of Embodiments 1 to 31, wherein the LNP has a size of 50 nm to 150 nm as determined using dynamic light scattering.
[0518] Embodiment 33. The LNP of Embodiment 32, wherein the size is 60 nm to 140 nm.
[0519] Embodiment 34. The LNP of Embodiment 32, wherein the size is 80 nm to 100 nm.
[0520] Embodiment 35. The LNP of Embodiment 32, wherein the size is 85 nm to 95 nm.
[0521] Embodiment 36. The LNP of any one of embodiments 1 to 35, wherein the LNP encapsulates mRNA.
[0522] Embodiment 37. A composition comprising lipid nanoparticles (LNPs), wherein each LNP is the LNP of any one of embodiments 1 to 36.
[0523] Embodiment 38. The composition of embodiment 37, wherein at least 80% of the LNPs encapsulate mRNA.
[0524] Embodiment 39. The composition of embodiment 37, wherein at least 85% of the LNPs encapsulate mRNA.
[0525] Embodiment 40. A method for expressing a protein in a cell, the method comprising introducing the LNP of embodiment 36 or the composition of embodiment 38 or 39 into the cell.
[0526] Embodiment 41. A method as described in Embodiment 40, wherein the cell is a mammalian cell.
[0527] Embodiment 42. A method for delivering a protein to a subject, the method comprising administering to the individual the LNP of embodiment 36 or the composition of embodiment 38 or 39, wherein the mRNA encodes the protein.
[0528] Embodiment 43. The method of embodiment 42, wherein the LNP or the composition is administered systemically.
[0529] Embodiment 44. A method as described in Embodiment 42, wherein the subject is a mammal.
[0530] Embodiment 45. A method as described in embodiment 42, wherein the subject is human.
[0531] Embodiment 46. A lipid nanoparticle (LNP) comprising a phospholipid, wherein the phospholipid has a structure selected from the group consisting of:
[0532]
[0533] as well as
[0534]
[0535] Embodiment 47. The LNP of embodiment 46, wherein the phospholipid has the following structure:
[0536]
[0537] Embodiment 48. The LNP of embodiment 46, wherein the phospholipid has the following structure:
[0538]
[0539] Embodiment 49. The LNP of any one of embodiments 46-48, further comprising an ionizable lipid.
[0540] Embodiment 50. The LNP of embodiment 49, wherein the LNP has a molar ratio of the ionizable lipid to the phospholipid of 20:1 to 2:1.
[0541] Embodiment 51. The LNP of embodiment 50, wherein the molar ratio of ionizable lipid to phospholipid is 15:1 to 5:1.
[0542] Embodiment 52. The LNP of embodiment 49, wherein the ionizable lipids account for 40 to 80 mol% of the total lipids in the LNP.
[0543] Embodiment 53. The LNP of embodiment 52, wherein the ionizable lipids account for 50 to 70 mol% of the total amount of lipids in the LNP.
[0544] Embodiment 54. An LNP as described in any one of embodiments 49 to 53, wherein the ionizable lipid is a compound according to any one of the formulas selected from 01-I, 01-II, 02-I, 02-II, 03-I, 03-II-A, 03-II-B, 03-II-C, 03-II-D, 04-I, 04-III, 04-IV, 05-I, 06-I and any one of their subformulas, or wherein the ionizable lipid is a cationic lipid selected from the compounds listed in any one of Tables 1 to 5.
[0545] Embodiment 55. The LNP of any one of embodiments 49 to 54, wherein the ionizable lipid is a cationic lipid.
[0546] Embodiment 56. The LNP of any one of embodiments 46 to 55, further comprising a polymer-bound lipid.
[0547] Embodiment 57. The LNP of embodiment 56, wherein the polymer-bound lipids account for 1 to 2% of the total lipids in the LNP.
[0548] Embodiment 58. The LNP of embodiment 57, wherein the polymer-bound lipids account for 1.5% of the total lipids in the LNP.
[0549] Embodiment 59. The LNP of any one of embodiments 46 to 58, wherein the LNP has a molar ratio of the polymer-bound lipid to the phospholipid of 1:5 to 1:10.
[0550] Embodiment 60. The LNP of any one of embodiments 56 to 59, wherein the polymer-bound lipid is a pegylated lipid.
[0551] Embodiment 61. The LNP of any one of embodiments 56 to 60, wherein the polymer-bound lipid is a PEGylated lipid having the following structure:
[0552]
[0553] or a pharmaceutically acceptable salt thereof, wherein
[0554] R 12 and R 13 Each is independently a straight or branched alkyl or alkenyl chain containing from 10 to 30 carbon atoms, wherein the alkyl chain is optionally interrupted by one or more ester bonds; and
[0555] w is an integer in the range of 30 to 60.
[0556] Embodiment 62. The LNP of any one of embodiments 56 to 61, wherein the polymer-bound lipid is a PEGylated lipid having the following structure:
[0557]
[0558] or a pharmaceutically acceptable salt thereof, wherein
[0559] w is an integer in the range of 30 to 60.
[0560] Embodiment 63. The LNP of embodiment 61 or 62, wherein w is an integer in the range of 45 to 55.
[0561] Embodiment 64. The LNP of embodiment 61 or 62, wherein w is about 49.
[0562] Embodiment 65. The LNP of any one of embodiments 56 to 60, wherein the polymer-bound lipid is DMG-PEG or DMPE-PEG.
[0563] Embodiment 66. The LNP of any one of embodiments 46 to 65, further comprising a lipid stabilizer.
[0564] Embodiment 67. The LNP of embodiment 66, wherein the LNP has a molar ratio of the lipid stabilizer to the phospholipid of 10:1 to 1:4.
[0565] Embodiment 68. The LNP of embodiment 67, wherein the molar ratio of the lipid stabilizer to the phospholipid is 5:1 to 1:1.
[0566] Embodiment 69. The LNP of embodiment 67, wherein the molar ratio of the lipid stabilizer to the phospholipid is 4:1 to 3:1.
[0567] Embodiment 70. The LNP of any one of embodiments 66 to 69, wherein the lipid stabilizer accounts for 5 to 50 mol% of the total lipid in the LNP.
[0568] Embodiment 71. The LNP of embodiment 70, wherein the lipid stabilizer accounts for 8 to 40 mol% of the total amount of lipids in the LNP.
[0569] Embodiment 72. The LNP of embodiment 70, wherein the lipid stabilizer accounts for 10 to 30 mol% of the total amount of lipids in the LNP.
[0570] Embodiment 73. The LNP of any one of embodiments 46 to 72, wherein the phospholipids account for 1 to 30 mol% of the total lipids in the LNP.
[0571] Embodiment 74. The LNP of embodiment 73, wherein the phospholipids account for 2 to 25 mol% of the total amount of lipids in the LNP.
[0572] Embodiment 75. The LNP of embodiment 73, wherein the phospholipids account for 3 to 20 mol% of the total amount of lipids in the LNP.
[0573] Embodiment 76. The LNP of embodiment 73, wherein the phospholipids account for 5 to 15 mol% of the total amount of lipids in the LNP.
[0574] Embodiment 77. The LNP of Embodiment 73, wherein the phospholipids account for about 10 mol% of the total amount of lipids in the LNP.
[0575] Embodiment 78. The LNP of any one of Embodiments 46 to 77, wherein the LNP has a size of 50 nm to 150 nm as determined using dynamic light scattering.
[0576] Embodiment 79. The LNP of Embodiment 78, wherein the size is 60 nm to 140 nm.
[0577] Embodiment 80. The LNP of Embodiment 78, wherein the size is 80 nm to 100 nm.
[0578] Embodiment 81. The LNP of Embodiment 78, wherein the size is 85 nm to 95 nm.
[0579] Embodiment 82. The LNP of any one of Embodiments 46 to 81, wherein the LNP encapsulates mRNA.
[0580] Embodiment 83. A composition comprising lipid nanoparticles (LNPs), wherein each LNP is a LNP as described in any one of embodiments 46 to 82.
[0581] Embodiment 84. The composition of embodiment 83, wherein at least 80% of the LNPs encapsulate mRNA.
[0582] Embodiment 85. The composition of embodiment 83, wherein at least 85% of the LNPs encapsulate mRNA.
[0583] Embodiment 86. A method for expressing a protein in a cell, the method comprising introducing the LNP of embodiment 82 or the composition of embodiment 84 or 85 into the cell.
[0584] Embodiment 87. A method as described in Embodiment 86, wherein the cell is a mammalian cell.
[0585] Embodiment 88. A method for delivering a protein to a subject, the method comprising administering to the individual the LNP of embodiment 82 or the composition of embodiment 84 or 85, wherein the mRNA encodes the protein.
[0586] Embodiment 89. The method of embodiment 88, wherein the LNP or the composition is administered systemically.
[0587] Embodiment 90. The method of embodiment 88, wherein the subject is a mammal.
[0588] Embodiment 91. The method of embodiment 88, wherein the subject is human.
[0589] Example
[0590] The present invention will be more fully understood with reference to the following examples. However, they should not be considered to limit the scope of the present invention. It should be understood that the embodiments and embodiments described herein are for illustrative purposes only, and various modifications or changes made according to them will be suggested to those skilled in the art, and these modifications or changes should be included in the spirit and authority of the application and the scope of the appended claims.
[0591] General Preparative High Performance Liquid Chromatography (HPLC) Method: HPLC purifications were performed on an Inertsil Pre-C8 OBD column on a Waters 2767 equipped with a diode array detector (DAD), typically using water containing 0.1% trifluoroacetic acid (TFA) as solvent A and acetonitrile as solvent B.
[0592] General Liquid Chromatography-Mass Spectrometry (LCMS) Methods: LCMS analysis was performed on a Shimadzu (LC-MS2020) system. Chromatography was performed on a SunFire C18, typically using water containing 0.1% formic acid as solvent A and acetonitrile containing 0.1% formic acid as solvent B.
[0593] The abbreviation OChemsPC refers to the following compound:
[0594]
[0595] The abbreviation PChemsPC refers to the following compound:
[0596]
[0597] The abbreviation DChemsPC refers to the following compound:
[0598]
[0599] "DSPC" refers to distearoylphosphatidylcholine. "Compound 01-1" refers to Compound 01-1 in Table 1. "Chol" is an abbreviation for cholesterol. "DMG-PEG" refers to 1,2-dimyristoyl-rac-glyceryl-3-methoxypolyethylene glycol-2000. ALC-0315 refers to Compound 06-1, and MC3 refers to Compound 07-1.
[0600] Example 1. Preparation of Compound 02-1 and Compound 02-3
[0601] Compound 02-1 was prepared according to the following scheme.
[0602]
[0603] Compound 02-1: 1 H NMR (400MHz, CDCl3) δ: 0.86-0.90 (m, 12H), 1.27-1.63 (m, 53H), 1.97-2.01 (m, 2H), 2.28-2.64 (m, 14H), 3.52-3.58 (m, 2H), 4.00-4.10 (m, 8H). LCMS:Rt:1.080min;MS m / z(ESI):826.0[M+H] + .
[0604] Compound 02-3 was prepared in a similar manner to compound 02-1 using the corresponding starting materials.
[0605]
[0606] Example 2. Preparation of Compound 02-2
[0607] Compound 02-2 was prepared according to the following scheme.
[0608]
[0609] Compound 02-2: 1H NMR(400MHz, CDCl3)δ:0.86-0.90(m,12H),1.28-1.67(m,54H),1.88-2.01(m,7H) ),2.28-2.56(m,18H),3.16-3.20(m,1H),3.52-3.54(m,2H),4.00-4.10(m,8H). LCMS:Rt:1.060min;MS m / z(ESI):923.0[M+H] + .
[0610] Example 3. Preparation of Compound 02-4
[0611] Compound 02-4 was prepared according to the following scheme.
[0612]
[0613] Compound 02-4: 1 H NMR(400MHz, CDCl3)δ:0.86-0.90(m,9H),1.26-1.32(m,34H),1.41-1.49(m,4H),1.61-1.66(m,15H),2.00- 2.03(m,1H),2.21-2.38(m,8H),2.43-2.47(m,4H),2.56-2.60(m,2H),3.50-3.54(m,2H),4.03-4.14(m,8H). LCMS:Rt:1.030min;MS m / z(ESI):798.0[M+H] + .
[0614] Example 4. Preparation of Compound 02-9 and Compound 02-14
[0615] Compound 02-9 was prepared according to the following scheme.
[0616]
[0617] Compound 02-9: 1 H NMR(400MHz, CDCl3)δ:0.86-0.90(m,12H),1.28-1.30(m,33H),1.58-2.01(m,18 H),2.30-2.54(m,18H),3.10-3.19(m,1H),3.52-3.68(m,8H),4.09-4.20(m,8H). LCMS:Rt:1.677min; MS m / z(ESI):927.7[M+H] + .
[0618] Compound 02-14 was prepared in a similar manner to compound 02-9 using the corresponding starting materials.
[0619]
[0620] Example 5. Preparation of Compound 02-10 and Compound 02-11
[0621] Compound 02-10 was prepared according to the following scheme.
[0622]
[0623] Compound 02-10: 1 H NMR(400MHz, CDCl3)δ:0.86-0.90(m,12H),1.26-1.41(m,48H),1.51-1.72(m,11H),1.94- 2.03(m,1H),2.29-2.32(m,6H),2.41-2.91(m,5H),3.51-3.76(m,2H),3.96-4.10(m,6H). LCMS:Rt:1.327min; MS m / z(ESI):782.6[M+H] + .
[0624] Compound 02-11 was prepared in a similar manner to compound 02-10 using the corresponding starting materials.
[0625]
[0626] Example 6. Preparation of Compound 02-12
[0627] Compound 02-12 was prepared according to the following scheme.
[0628]
[0629] Compound 02-12: 1 H NMR(400MHz, CDCl3)δ:0.86-0.89(m,18H),1.25-1.35(m,53H),1.41-1.48(m,8H),1.56-1.61(m,20H),1.95- 2.01(m,2H),2.28-2.35(m,6H),2.43-2.46(m,4H),2.56-2.58(m,2H),3.51-3.54(m,2H),4.00-4.10(m,8H). LCMS:Rt:0.080min;MS m / z(ESI):1050.8[M+H] + .
[0630] Example 7. Preparation of Compound 02-20
[0631] Compound 02-20 was prepared according to the following scheme.
[0632]
[0633] Compound 02-20: 1 H NMR (400MHz, CDCl3) δ: 0.86-0.90(m,9H),1.25-1.36(m,48H),1.41-1.48(m,5H),1.60-1.62(m,8H),1.97-2 .00(m,1H),2.27-2.32(m,6H),2.43-2.46(m,4H),2.56-2.59(m,2H),3.52-3.54(m,2H),4.01-4.10(m,6H). LCMS: Rt:0.093min; MS m / z(ESI):782.6[M+H] + .
[0634] Example 8. Preparation of Compound 04-1
[0635] Compound 04-1 was prepared according to the following scheme.
[0636]
[0637] LCMS-Rt of compound 1-1 of Example 8: 0.750 min; MS m / z (ESI): 206.2 [M+H] + .
[0638] LCMS-Rt of compound 1-2 of Example 8: 0.870 min; MS m / z (ESI): 448.3 [M+H] + .
[0639] LCMS-Rt of compound 1-3 of Example 8: 1.360 min; MS m / z (ESI): 616.5 [M+H] + .
[0640] Compound 04-1: 1H NMR(400MHz, CDCl3)δ: 0.79-0.83(m,6H),1.14-1.26(m,38H),1.47-1.61(m,6H),1.8 6-1.96(m,4H),2.51-2.58(m,4H),3.17(s,1H),3.32-3.44(m,5H),3.51-3.66(m,3H). LCMS:Rt:0.94min;MS m / z(ESI):526.5[M+H] + .
[0641] Example 9. Preparation of Compound 04-2
[0642] Compound 04-2 was prepared according to the following scheme.
[0643]
[0644] LCMS-Rt of compound 2-1 of Example 9: 1.340 min; MS m / z (ESI): 630.5 [M+H] + .
[0645] Compound 04-2: 1 H NMR(400MHz, CDCl3)δ:0.86-0.90(m,6H),1.25-1.33(m,35H),1.50-1.69(m,7H),1.87-1.99(m,1H),2.00-2.08(m,2H) ,2.33(t,J=7.6Hz,2H),2.56-2.81(m,4H),3.17-3.27(m,1H),3.38-3.48(m,3H),3.50-3.65(m,3H),5.08-5.14(m,1H). LCMS:Rt:1.180min;MS m / z(ESI):540.4[M+H] + .
[0646] Example 10. Preparation of Compound 04-7
[0647] Compound 04-7 was prepared according to the following scheme.
[0648]
[0649] LCMS-LCMS of compound 7-1 of Example 10: Rt: 0.780 min; MS m / z (ESI): 427.4 [M+H] + .
[0650] Compound 04-7: 1H NMR(400MHz, CDCl3)δ:0.86-0.90(m,9H),1.26-1.35(m,45H),1.41-1.67(m,7H),2.28-2.32(m,3H) ),2.36-2.70(m,11H),2.79-2.83(m,2H),3.35-3.46(m,4H),3.77-3.85(m,1H),3.96-3.97(m,2H). LCMS:Rt:1.220min;MS m / z(ESI):669.6[M+H] + .
[0651] Example 11. Preparation of Compound 04-8
[0652] Compound 04-8 was prepared according to the following scheme.
[0653]
[0654] LCMS-LCMS of compound 8-1 of Example 11: Rt: 0.730 min; MS m / z (ESI): 371.3 [M+H] + .
[0655] Compound 04-8: 1 H NMR(400MHz, CDCl3)δ:0.86-0.90(m,9H),1.25-1.27(m,47H),1.40-1.49(m,4H),1.56-1.73(m,8H),2.30(t,J =7.6Hz,3H),2.40-2.82(m,10H),3.32-3.38(m,1H),3.43-3.46(m,3H),3.70-3.80(m,1H),3.92-3.97(m,2H). LCMS:Rt:1.090min;MS m / z(ESI):709.6[M+H] + .
[0656] Example 12. Preparation of Compound 04-65, Compound 04-66 and Compound 04-67
[0657] Compound 04-65 was prepared according to the following scheme.
[0658]
[0659] Compound 04-65: 1H NMR (400MHz, CCl3D): δ: 0.79-0.83(m,12H),1.23-1.27(m,62H),1.29-1.37(m,2H),1.51-1.61(m,2H),1.76-1.93(m,7 H),2.13-2.16(m,4H),2.17-2.25(m,3H),2.41-2.51(m,7H),3.05-3.06(m,1H),3.52-3.54(m.2H),3.92-4.03(m,4H). LCMS:Rt:0.588min; MS m / z(ESI):863.6[M+H] + .
[0660] Compounds 04-66 and 04-67 were prepared in a similar manner to compound 04-65 using the corresponding starting materials.
[0661]
[0662] Example 13. Preparation of Compound 04-68
[0663] Compound 04-68 was prepared according to the following scheme.
[0664]
[0665] Compound 68-2 of Example 13 1 H NMR- 1 H NMR(400MHz, CDCl3)δ:0.86-0.90(m,12H),1.26-1.46(m,53H),1.56-1.62(m,2H), 1.83(s,2H),1.96-2.02(m,1H),2.23-2.24(m,4H),3.64(s,2H),4.02-4.11(m,4H).
[0666] Compound 04-68: 1 H NMR(400MHz, CDCl3)δ:0.83-0.92(m,12H),1.17-1.37(m,56H),1.38-1.45(m,2H),1.64-1.67(m,2H),1.70-1.86(m,6 H),1.92-2.04(m,2H),2.19-2.26(m,4H),2.40-2.49(m,3H),2.57-2.65(m,2H),3.41-3.51(m,2H),3.97-4.12(m,4H). LCMS:Rt:0.080min;MS m / z(ESI):778.5[M+H] + .
[0667] Example 14. Preparation of Compound 04-69, Compound 04-79 and Compound 04-80
[0668] Compound 04-69 was prepared according to the following scheme.
[0669]
[0670] LCMS-Rt of compound 69-1 of Example 14: 1.290 min; MS m / z (ESI): 750.7 [M+H] + .
[0671] Compound 04-69: 1 H NMR(400MHz, CDCl3)δ:0.83-0.92(m,12H),0.98-1.06(m,3H),1.17-1.47(m,52H),1.54-1.72(m,5H),1.78-2.06(m,8 H),2.20-2.27(m,4H),2.37-2.46(m,4H),2.49-2.66(m,5H),3.01-3.12(m,1H),3.52-3.59(m,2H),3.98-4.11(m,4H). LCMS:Rt:0.093min;MS m / z(ESI):821.6[M+H] + .
[0672] Compounds 04-79 and 04-80 were prepared in a similar manner to compound 04-69 using the corresponding starting materials.
[0673]
[0674] Example 15. Initial Screening of LNPs Containing Steroid Phospholipids
[0675] In brief, the lipid component of a specified amount is dissolved in ethanol with a specified molar ratio (see Table 6). mRNA is diluted in 10 to 50mM citrate buffer (pH=3-5). The total lipid and mRNA weight ratio is about 10:1 to 30:1 LNPs prepared by mixing ethanol lipid solution with aqueous mRNA solution in a volume ratio of 1:3 using a microfluidic device, and the total flow rate is within the range of 9-30mL / min. Thus, ethanol is removed and dialysis is replaced by Dulbecco's phosphate-buffered saline (DPBS). Finally, lipid nanoparticles are filtered through a 0.2 μm sterile filter.
[0676] The lipid nanoparticle size was determined by dynamic light scattering using a Malvern Zetasizer Nano ZS (Malvern UK) using 173° backscatter detection mode. The encapsulation efficiency of the lipid nanoparticles was determined using the Quant-it Ribogreen RNA quantification kit (ThermoFisher Scientific, UK) according to the manufacturer's instructions.
[0677] In order to measure size and polydispersity index (PDI), lipid nanoparticle preparations were diluted 20 times in PBS and 1 mL was transferred to a measuring cuvette. Quant-it RiboGreen RNA analysis kit was used to determine LNP encapsulation efficiency (EE%), and LNP preparations were diluted to 0.5 μg / mL in Tris-EDTA and 0.1% Triton, respectively. In order to determine free RNA and total RNA fluorescence intensity, ribogreen reagent was diluted 200 times with Tris-EDTA buffer and mixed with the same volume of diluted LNP preparations. Fluorescence intensity was measured at room temperature in a Molecular Devices Spectramax iD3 spectrometer using excitation and emission wavelengths of 488 nm and 525 nm. EE% was calculated based on the ratio of encapsulated RNA to total RNA fluorescence intensity.
[0678] Table 6: Expression levels of LNPs containing steroid phospholipids
[0679]
[0680] Lipid nanoparticles encapsulating human erythropoietin (hEPO) mRNA were prepared as described above and systemically administered to 6-8 week old female ICR mice (Xipuer-Bikai, Shanghai) at a dose of 0.5 mg / kg by tail vein injection. Mice were euthanized by CO2 overdose 6 hours after administration, and blood samples were taken for hEPO measurement. Specifically, serum was separated from total blood by centrifugation at 5000g for 10 minutes at 4°C, quickly frozen and stored at -80°C for analysis. Serum hEPO levels were measured by ELISA analysis using a commercial kit (DEP00, R&Dsystems) according to the manufacturer's instructions. Figure 1 The hEPO expression levels (μg / ml) measured from the test groups are plotted in and summarized in Table 6.
[0681] As shown in the figure, replacing DSPC with PChemsPC and adjusting the molar ratio significantly increased the protein expression of EPO-LNPs in vivo by 2-3 fold.
[0682] Example 16. Expression levels of loaded LNPs containing steroid-containing phospholipids
[0683] This study examined the in vivo expression levels of LNP formulations containing 45%-75% Compound 01-1 with DSPC or PChemsPC. Lipid nanoparticles containing human erythropoietin (hEPO) mRNA were prepared as described in Example 15. Results Figure 2 and shown in Table 7.
[0684] Among the DSPC LNPs tested, LNPs containing 45-60 mol% Compound 01-1 produced the highest protein expression levels. For PChemsPC LNPs, 60-75 mol% Compound 01-1 produced the highest protein expression levels.
[0685] Table 7. Other expression levels of LNPs containing steroid phospholipids
[0686]
[0687]
[0688] Example 17. Screening of PChemsPC percentage for optimal protein expression
[0689] Further screening was performed to examine the in vivo expression levels of LNP formulations containing 5-25 mol% PChemsPC with varying amounts of compound 01-1. Lipid nanoparticles containing human erythropoietin (hEPO) mRNA were prepared as described in Example 15. Figure 3 and shown in Table 8.
[0690] Among the PChemsPC LNPs tested, 5-10 mol% PChemsPC had the highest protein expression level. The optimal amount of PChemsPC varied with the amount of compound 01-1. When the mol% of PChemsPC exceeded 15%, protein expression seemed to decrease.
[0691] Table 8. Additional expression levels of LNPs containing steroid phospholipids.
[0692]
[0693] Example 18. Screening of LNP compositions with steroid-containing phospholipids for optimal protein expression
[0694] This study examines the in vivo EPO expression levels of PChemsPC LNPs with different compositions. Lipid nanoparticles containing human erythropoietin (hEPO) mRNA were prepared as described in Example 15. In this study, the molar ratio of 50%-75% compound 01-1, 18.5%-38.5% cholesterol, 5-15% PChemsPC was tested to achieve acceptable protein expression levels. The corresponding LNP characterizations are listed in Table 9.
[0695] Table 9. Additional expression levels of LNPs containing steroid-containing phospholipids at different molar ratios.
[0696]
[0697] As can be seen from Table 9, high protein expression can be produced in LNP formulations containing 60-75 mol% cationic lipid, 5-10 mol% PChemsPC and 18.5-28.5 mol% cholesterol, and their physicochemical properties (such as size, polydispersity index and encapsulation efficiency) are acceptable.
[0698] Example 19. Tissue-specific expression of nucleic acid molecules delivered in LNP formulations.
[0699] To study the tissue biodistribution of LNPs in mice, LNP formulations listed in Table 10 containing mRNA encoding luciferase were prepared as described in Example 15.
[0700] Table 10. LNP composition and physical characterization
[0701]
[0702]
[0703] Each formulation was systemically administered to 6-8 week old female ICR mice (Shanghai Xipuer-Bikai Laboratory Animal Co., Ltd.) at a dose of 0.25 mg / kg by tail vein injection. After 6 hours, the mice were subcutaneously administered XenoLight D-luciferin (potassium salt), a substrate for luciferase that catalyzes the production of luminescence. The mice were then euthanized by CO2 overdose 15 min thereafter. Mouse tissues were harvested and placed in a luminescent imaging scanner to measure the expression level of luciferase in each tissue. Figure 4 Luminescence levels measured from harvested liver tissues are plotted in , showing the mean and standard deviation (SD) of at least five replicate tested animals per group.
[0704] like Figure 4As shown in , LNPs composed of steroid-containing phospholipids (e.g., PChemsPC, OChemsPC, DChemsPC) produced higher liver signals compared to DSPC controls. Compound 01-1 plus PChemsPC at a molar ratio of 50%-75% produced higher liver luminescence signals.
[0705] The percentage of luminescence intensity in different tissues was calculated and Figure 5 Draw in.
[0706] like Figure 5 As shown in , after injection, DSPC LNP produced 96% liver distribution and about 3% spleen distribution, while steroid-containing phospholipid LNP showed 98-99% liver distribution and 0.4% spleen distribution. It can be seen that steroid-modified phospholipid LNP showed better liver tropism.
[0707] Example 20. Characterization of sterol-modified phospholipid LNPs with different ionizable lipids
[0708] Different ionizable lipids were used to prepare LNP formulations containing PChemsPC. The LNP formulation consisted of 65% ionizable lipids, 10% PChemsPC lipids, 23.5% cholesterol-based lipids, and 1.5% PEGylated lipids in a molar ratio. Lipid nanoparticles containing human erythropoietin (hEPO) mRNA were prepared as described in Example 15.
[0709] Compound 01-1 plus DSPC control was used as the comparison group here in this study. The corresponding LNP characterizations in the case of different ionizable lipids are listed in Table 11.
[0710] Table 11. Characterization of LNPs with different ionizable lipids.
[0711]
[0712]
[0713] As shown in Table 11, most ionizable lipids showed better protein expression levels compared to the compound 01-1 control, indicating that PChemsPC is broadly compatible with most ionizable lipids. The combination of PChemsPC and compound 02-3 can produce up to 2.8-fold increase in protein expression levels.
[0714] In addition, the effect of replacing DSPC with PChemsPC on in vivo protein expression levels was also studied for commercial lipids ALC-0315 and MC3. In this study, LNP formulations consisted of 50%-65% ionizable lipids, 10% phospholipids, 23.5%-38.5% cholesterol-based lipids, and 1.5% PEGylated lipids in a molar ratio. LNP characterization was listed in Table 12.
[0715] Table 12. Physical characterization of ALC-0315 and MC3 LNPs.
[0716] Lipid components Molar Ratio Size(nm) PDI EE(%) ALC-0315 / DSPC / Chol / DMG-PEG 50 / 10 / 38.5 / 1.5 67.53 0.123 95.40 ALC-0315 / PChemsPC / Chol / DMG-PEG 65 / 10 / 23.5 / 1.5 86.62 0.091 87.46 MC3 / DSPC / Chol / DMG-PEG 50 / 10 / 38.5 / 1.5 72.76 0.102 98.80 MC3 / PChemsPC / Chol / DMG-PEG 65 / 10 / 23.5 / 1.5 92.83 0.011 99.20
[0717] Figure 6 The fold changes of hEPO expression levels in vivo are shown in FIG.
[0718] like Figure 6 As shown in , replacing DSPC with PChemsPC significantly improved the in vivo protein expression level by 1.6-1.8 fold.
[0719] Example 21. Characterization of serum cytokines in vivo after injection of steroid phospholipid LNPs
[0720] As an allogeneic substance, LNP injection will significantly increase proinflammatory cytokines (such as interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), interferon-γ (INF-γ), interferon-α (IFN-α)), which can cause innate immune responses and produce undesirable side effects. This study evaluated serum cytokine levels after systemic administration of LNPs, thereby comparing serum cytokines enhanced by DSPC LNPs and PChemsPC LNPs.
[0721] Lipid nanoparticles containing human erythropoietin (hEPO) mRNA were prepared as described in Example 15 and systemically administered to 6-8 week old female ICR mice (Shanghai Xipuer-Bikai Experimental Animal Co., Ltd.) by tail vein injection at a dose of 0.5 mg / kg. Mice were euthanized by CO2 overdose 6 hours after administration, and blood samples were taken for cytokine measurement. Specifically, serum was separated from total blood by centrifugation at 5000g for 10 minutes at 4°C, quickly frozen and stored at -80°C for analysis.
[0722] DSPC LNPs consist of 50% ionizable lipids, 10% DSPC, 38.5% cholesterol, and 1.5% PEGylated lipids. PChemsPC LNPs consist of 65% ionizable lipids, 10% PChemsPC, 23.5% and 1.5% cholesterol and PEGylated lipids, respectively. Several ionizable lipids (e.g., compound 01-1, lipid 5, SM-102, ALC-0315, compound 03-135) were tested in this study.
[0723] The results are Figures 7 to 11 As shown in Figures 7 to 11 As shown in , PChemsPC LNPs can significantly reduce IL-6 levels compared to the corresponding DSPC controls. In particular, for ALC-0315LNPs, a decrease of about 9 times in IL-6 levels was observed, indicating that PChemsPC LNPs have better safety after administration.
[0724] Example 22. Characterization of serum cytokines in vivo after administration of steroid phospholipid-containing LNPs with self-amplifying mRNA (saRNA)
[0725] In this study, lipid nanoparticles containing human erythropoietin (hEPO) self-amplifying mRNA were prepared as described in Example 15. After tail vein injection, mice were euthanized by CO2 overdose 6 hours after administration, and blood samples were taken for cytokine measurement. Cytokine levels were measured and Fig.12 and Fig.13 Draw in.
[0726] like Fig.12 and Fig.13 As shown in , PChemsPC LNPs produced significantly lower levels of IL-6, IFN-α, and TNF-α.
[0727] Example 23. Characterization of sterol-modified phospholipid LNPs with CD3-CD19 mRNA
[0728] In this study, DSPC LNPs were composed of 50% molar ratio of compound 01-1, 10% molar ratio of DSPC, 38.5% molar ratio of cholesterol, and 1.5% molar ratio of PEGylated lipids. PChemsPC LNPs were composed of 65% molar ratio of compound 01-1, 10% molar ratio of PChemsPC, and 23.5% and 1.5% molar ratios of cholesterol and PEGylated lipids, respectively.
[0729] Lipid nanoparticles encapsulating CD19-CD3 mRNA were prepared as described in Example 15 and systemically administered to 6-8 week old female Balb / c mice (Shanghai Xipuer-Bikai Experimental Animal Co., Ltd.) at a dose of 0.3 mg / kg by tail vein injection. Mice were euthanized by CO2 overdose 6 hours after administration, and blood samples were taken for antibody measurement. Specifically, serum was separated from total blood by centrifugation at 5000g for 10 minutes at 4°C, quickly frozen and stored at -80°C for analysis. Fig.14 Serum antibody levels are shown in .
[0730] like Fig.14 As shown in , PChemsPC LNPs can significantly improve the expression level of CD3-CD19 antibodies after administration.
Claims
1. A lipid nanoparticle (LNP), comprising: Phospholipids containing a sterol moiety; Ionizable lipids; and Polymer-bound lipids.
2. The LNP of claim 1, wherein the phospholipid has a structure selected from the group consisting of: as well as 3. LNP as claimed in claim 1 or 2, wherein the phospholipid accounts for 1 to 30 mol%, preferably 2 to 25 mol%, preferably 3 to 20 mol%, and more preferably 5 to 15 mol% of the total lipid content in the LNP.
4. The LNP of any one of claims 1 to 3, wherein the LNP has a molar ratio of the ionizable lipid to the phospholipid of 20:1 to 2:1, preferably 18:1 to 2.5:1, preferably 16:1 to 4:1, more preferably 15:1 to 5:
1.
5. The LNP of any one of claims 1 to 4, wherein the ionizable lipid is a cationic lipid, preferably the ionizable lipid is a compound according to any one of the formulas selected from 01-I, 01-II, 02-I, 02-II, 03-I, 03-II-A, 03-II-B, 03-II-C, 03-II-D, 04-I, 04-III, 04-IV, 05-I, 06-I and subformulas thereof, more preferably the ionizable lipid is a cationic lipid selected from the compounds listed in any one of Tables 1 to 5.
6. The LNP of any one of claims 1 to 4, wherein the ionizable lipid is selected from: Compound of formula (01-10): wherein y and z are each independently an integer from 4 to 6, s is an integer from 2 to 4, t is an integer from 1 to 3, and R 1 and R 2 Each independently is C 12 -C 22 alkyl; R 4 is a C3-C8 cycloalkyl group; R 6 is hydrogen or hydroxyl, Compound of formula 05-I: in l is selected from 1, 2, 3, 4 and 5; m is selected from 5, 6, 7, 8 and 9; M1 is -C(O)O-; R4 is -(CH2) n OH, and n is selected from 1, 2, 3, 4 or 5; M is -OC(O)-; and R2 and R3 are both C 6-10 alkyl, Compound of formula (06-1): in L 1 and L 2 is -O(C═O)-; G 1 and G 2 Each is independently an unsubstituted C4-C8 alkylene group; G 3 is C3-C8 alkylene; R 1 and R 2 Each independently is C 12 -C 22 alkyl; R 3 is H or OH, Compound of formula (02-VB) in Each L 1 Independently -OC(=O)R 1 ; Each L 2 Independently -OC(=O)R 2 ; R 1 and R 2 Each independently is C6-C 24 alkyl; R 3 is -OR 6 ; R 6 is hydrogen; z is an integer from 2 to 12; x1 is an integer from 0 to 9; y1 is an integer from 0 to 9; Compound of formula (02-VI-F) in Each L 1 Independently -OC(=O)R 1 ; Each L 2 Independently -OC(=O)R 2 ; R 1 and R 2 Each independently is C6-C 24 Alkyl or C6-C 24 Alkenyl; R 3 For-OR 6 ; R 6 is hydrogen; z is an integer from 2 to 12; y is an integer from 2 to 12; x1 is an integer from 2 to 5; Compound of formula (02-VF) in Each L 1 Independently -OC(=O)R 1 ; Each L 2 Independently -OC(=O)R 2 ; R 1 and R 2 Each independently is C6-C 24 alkyl; R 3 is - OR 6 ; R 6 is hydrogen; z is an integer from 2 to 12; x2 is an integer from 2 to 9; x4 is an integer from 0 to 3; y2 is an integer from 2 to 9; y4 is an integer from 0 to 3, Compound of formula (03-I) in G 1 and G 2 Each is independently C3-C8 alkylene; Each L 1 Independently -OC(=O)R 1 OR -C(=O)OR 1 ; Each L 2 are independently -C(=O)OR 2 or –OC(=O)R 2 ; R 1 Independently C6-C 24 alkyl; R 2 Independently C6-C 24 alkyl; G 3 C2-C 12 Alkylene; R 3 is a C3-C8 cycloalkyl group; R 4 is C1-C4 hydroxyalkyl; n is 1 or 2; m is 1 or 2, and Compound 07-I:
7. The LNP of claim 6, wherein the ionizable lipid is selected from the following compounds: as well as 8. The LNP of any one of claims 1 to 7, wherein the ionizable lipid accounts for 40 to 80 mol%, 45 to 75 mol%, 50 to 70 mol% or 60 to 65 mol% of the total lipid in the LNP.
9. The LNP of any one of claims 1 to 8, wherein the polymer-bound lipid is a PEGylated lipid, preferably having the following structure: or a pharmaceutically acceptable salt thereof, wherein R 12 and R 13 Each is independently a straight or branched alkyl or alkenyl chain containing from 10 to 30 carbon atoms, wherein the alkyl chain is optionally interrupted by one or more ester bonds; and w is an integer in the range of 30 to 60, preferably 45 to 55, more preferably w is 49.
10. The LNP of any one of claims 1 to 9, wherein the polymer-bound lipid is a PEGylated lipid having the following structure: or a pharmaceutically acceptable salt thereof, wherein w is an integer in the range of 30 to 60, preferably 45 to 55, more preferably w is 49, Preferably, the polymer-bound lipid is DMG-PEG or DMPE-PEG.
11. The LNP according to any one of claims 1 to 10, wherein the polymer-bound lipid accounts for 0.5 to 5 mol%, preferably 1 to 2 mol%, more preferably 1.5 mol% of the total amount of lipid in the LNP.
12. The LNP of any one of claims 1 to 11, wherein the LNP has a molar ratio of the polymer-bound lipid to the phospholipid of 1:2 to 1:20, preferably 1:3 to 1:18 or 1:5 to 1:
10.
13. The LNP of any one of claims 1 to 12, further comprising a lipid stabilizer.
14. The LNP of claim 13, wherein the lipid stabilizer is selected from sterols, corticosteroids, tomatine, tomatine, ursolic acid and α-tocopherol, preferably selected from cholesterol, coproposterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, prednisolone, dexamethasone, prednisone, hydrocortisone, tomatine, tomatine, ursolic acid and α-tocopherol.
15. The LNP of claim 13 or 14, wherein the lipid stabilizer accounts for 5 to 50 mol%, preferably 8 to 40 mol%, more preferably 10 to 30 mol% of the total lipid in the LNP.
16. The LNP of any one of claims 13 to 15, wherein the LNP has a molar ratio of the lipid stabilizer to the phospholipid of 10:1 to 1:4, preferably 5:1 to 1:
3.
17. The LNP of any one of claims 1 to 16, wherein the LNP has a size of 20 nm to 300 nm, preferably 50 nm to 150 nm, preferably 60 nm to 140 nm, more preferably 80 nm to 100 nm, even more preferably 85 nm to 95 nm, as determined using dynamic light scattering.
18. A composition comprising lipid nanoparticles (LNPs) and a therapeutic payload, wherein each LNP is a LNP as described in any one of claims 1 to 17.
19. The composition of claim 18, wherein at least 80%, preferably at least 85%, of the LNPs encapsulate the therapeutic payload.
20. The composition of claim 18 or 19, wherein the therapeutic payload is selected from nucleic acids, preferably DNA and RNA, more preferably catalytic DNA, plasmid DNA, aptamers, complementary DNA, mRNA, antisense oligonucleotides, miRNA, miRNA inhibitors, micRNA, multivalent RNA, dsRNA, shRNA, antisense RNA, tRNA, aiRNA, ribozymes, aptamers and vectors.
21. The composition of claim 18 or 19, wherein the therapeutic payload is mRNA.
22. A method for expressing a protein in a cell, the method comprising introducing the composition of claim 21 into the cell.
23. The method of claim 22, wherein the cell is a mammalian cell.
24. A method for delivering a protein to a subject, the method comprising administering to the subject the composition of claim 21, wherein the mRNA encodes the protein.
25. The method of claim 24, wherein the composition is administered systemically.
26. The method of claim 24 or 25, wherein the subject is a mammal, particularly a human.
27. A lipid nanoparticle (LNP) comprising a phospholipid, wherein the phospholipid has a structure selected from the group consisting of: as well as 28. The LNP of claim 27, further comprising an ionizable lipid.
29. The LNP of claim 28, wherein the LNP has a molar ratio of the ionizable lipid to the phospholipid of 20:1 to 2:1, preferably 18:1 to 2.5:1, preferably 16:1 to 4:1, more preferably 15:1 to 5:
1.
30. The LNP of claim 27 or 28, wherein the ionizable lipid accounts for 40 to 80 mol%, 45 to 75 mol%, 50 to 70 mol% or 60 to 65 mol% of the total lipid in the LNP.
31. The LNP of any one of claims 28 to 30, wherein the ionizable lipid is a cationic lipid, preferably the ionizable lipid is a compound according to any one of the formulas selected from 01-I, 01-II, 02-I, 02-II, 03-I, 03-II-A, 03-II-B, 03-II-C, 03-II-D, 04-I, 04-III, 04-IV, 05-I, 06-I and subformulas thereof, more preferably the ionizable lipid is a cationic lipid selected from the compounds listed in any one of Tables 1 to 5.
32. The LNP of any one of claims 28 to 30, wherein the ionizable lipid is selected from: Compound of formula (01-10): wherein y and z are each independently an integer from 4 to 6, s is an integer from 2 to 4, t is an integer from 1 to 3, and R 1 and R 2 Each independently is C 12 -C 22 alkyl; R 4 is a C3-C8 cycloalkyl group; R 6 is hydrogen or hydroxyl, Compound of formula 05-I: in l is selected from 1, 2, 3, 4 and 5; m is selected from 5, 6, 7, 8 and 9; M1 is -C(O)O-; R4 is -(CH2) n OH, and n is selected from 1, 2, 3, 4 or 5; M is -OC(O)-; and R2 and R3 are both C 6-10 alkyl, Compound of formula (06-1): in L 1 and L 2 is -O(C═O)-; G 1 and G 2 Each is independently an unsubstituted C4-C8 alkylene group; G 3 is C3-C8 alkylene; R 1 and R 2 Each independently is C 12 -C 22 alkyl; R 3 is H or OH, Compound of formula (02-VB) in Each L 1 Independently -OC(=O)R 1 ; Each L 2 Independently -OC(=O)R 2 ; R 1 and R 2 Each independently is C6-C 24 alkyl; R 3 is -OR 6 ; R 6 is hydrogen; z is an integer from 2 to 12; x1 is an integer from 0 to 9; y1 is an integer from 0 to 9; Compound of formula (02-VI-F) in Each L 1 Independently -OC(=O)R 1 ; Each L 2 Independently -OC(=O)R 2 ; R 1 and R 2 Each independently is C6-C 24 Alkyl or C6-C 24 alkenyl; R 3 is - OR 6 ; R 6 is hydrogen; z is an integer from 2 to 12; y is an integer from 2 to 12; x1 is an integer from 2 to 5; Compound of formula (02-VF) in Each L 1 Independently -OC(=O)R 1 ; Each L 2 Independently -OC(=O)R 2 ; R 1 and R 2 Each independently is C6-C 24 alkyl; R 3 is - OR 6 ; R 6 is hydrogen; z is an integer from 2 to 12; x2 is an integer from 2 to 9; x4 is an integer from 0 to 3; y2 is an integer from 2 to 9; y4 is an integer from 0 to 3, Compound of formula (03-I) in G 1 and G 2 Each is independently C3-C8 alkylene; Each L 1 Independently -OC(=O)R 1 OR -C(=O)OR 1 ; Each L 2 are independently -C(=O)OR 2 or –OC(=O)R 2 ; R 1 Independently C6-C 24 alkyl; R 2 Independently C6-C 24 alkyl; G 3 C2-C 12 Alkylene; R 3 is a C3-C8 cycloalkyl group; R 4 is C1-C4 hydroxyalkyl; n is 1 or 2; m is 1 or 2, and Compound 07-I:
33. The LNP of any one of claims 28 to 30, wherein the ionizable lipid is selected from the following compounds: as well as 34. The LNP of any one of claims 27 to 33, further comprising a polymer-bound lipid.
35. The LNP of claim 34, wherein the polymer-bound lipid accounts for 0.5 to 5 mol%, preferably 1 to 2 mol%, more preferably 1.5 mol% of the total amount of lipid in the LNP.
36. The LNP of claim 34 or 35, wherein the LNP has a molar ratio of the polymer-bound lipid to the phospholipid of 1:2 to 1:20, preferably 1:3 to 1:18 or 1:5 to 1:
10.
37. The LNP of any one of claims 34 to 36, wherein the polymer-bound lipid is a PEGylated lipid, preferably having the following structure: or a pharmaceutically acceptable salt thereof, wherein R 12 and R 13 Each is independently a straight or branched alkyl or alkenyl chain containing from 10 to 30 carbon atoms, wherein the alkyl chain is optionally interrupted by one or more ester bonds; and w is an integer in the range of 30 to 60, preferably 45 to 55, more preferably w is 49.
38. The LNP of any one of claims 34 to 36, wherein the polymer-bound lipid is a PEGylated lipid having the structure: or a pharmaceutically acceptable salt thereof, wherein w is an integer in the range of 30 to 60, preferably 45 to 55, more preferably w is 49, preferably the polymer-bound lipid is DMG-PEG or DMPE-PEG.
39. The LNP of any one of claims 27 to 38, further comprising a lipid stabilizer.
40. The LNP of claim 39, wherein the lipid stabilizer is selected from sterols, corticosteroids, tomatine, tomatine, ursolic acid and α-tocopherol, preferably selected from cholesterol, coproposterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, prednisolone, dexamethasone, prednisone, hydrocortisone, tomatine, tomatine, ursolic acid and α-tocopherol.
41. The LNP of claim 39 or 40, wherein the LNP has a molar ratio of the lipid stabilizer to the phospholipid of 10:1 to 1:4, preferably 5:1 to 1:
3.
42. The LNP of any one of claims 39 to 41, wherein the lipid stabilizer accounts for 5 to 50 mol%, preferably 8 to 40 mol%, more preferably 10 to 30 mol% of the total lipid in the LNP.
43. The LNP of any one of claims 27 to 42, wherein the phospholipid accounts for 1 to 30 mol%, preferably 2 to 25 mol%, preferably 3 to 20 mol%, more preferably 5 to 15 mol% of the total amount of lipids in the LNP.
44. The LNP of any one of claims 27 to 43, wherein the LNP has a size of 20 nm to 300 nm, preferably 50 nm to 150 nm, preferably 60 nm to 140 nm, more preferably 80 nm to 100 nm, even more preferably 85 nm to 95 nm, as determined using dynamic light scattering.
45. A composition comprising lipid nanoparticles (LNPs) and a therapeutic payload, wherein each LNP is a LNP as described in any one of claims 27 to 44.
46. The composition of claim 45, wherein at least 80%, preferably at least 85%, of the LNPs encapsulate the therapeutic payload.
47. The composition of claim 45 or 46, wherein the therapeutic payload is selected from nucleic acids, preferably DNA and RNA, more preferably catalytic DNA, plasmid DNA, aptamers, complementary DNA, mRNA, antisense oligonucleotides, miRNA, miRNA inhibitors, micRNA, multivalent RNA, dsRNA, shRNA, antisense RNA, tRNA, aiRNA, ribozymes, aptamers and vectors.
48. The composition of claim 45 or 46, wherein the therapeutic payload is mRNA.
49. A method for expressing a protein in a cell, the method comprising introducing the composition of claim 48 into the cell.
50. The method of claim 48, wherein the cell is a mammalian cell.
51. A method for delivering a protein to a subject, the method comprising administering to the subject the composition of claim 48, wherein the mRNA encodes the protein.
52. The method of claim 51, wherein the composition is administered systemically.
53. The method of claim 51 or 52, wherein the subject is a mammal, particularly a human.
Citation Information
Patent Citations
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US10166298B2
Compounds and compositions for intracellular delivery of therapeutic agents
US10442756B2
Compounds and compositions for intracellular delivery of therapeutic agents
US9868691B2
Compounds and compositions for intracellular delivery of therapeutic agents
US9868692B2
Improved lipid formulation
WO2010144740A1
